<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Low‐molecular‐weight heparins for managing vaso‐occlusive crises in people with sickle cell disease - van Zuuren, EJ - 2015 | Cochrane Library</title> <meta content="Low‐molecular‐weight heparins for managing vaso‐occlusive crises in people with sickle cell disease - van Zuuren, EJ - 2015 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010155.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Low‐molecular‐weight heparins for managing vaso‐occlusive crises in people with sickle cell disease - van Zuuren, EJ - 2015 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010155.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD010155.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Low‐molecular‐weight heparins for managing vaso‐occlusive crises in people with sickle cell disease" name="citation_title"/> <meta content="Esther J van Zuuren" name="citation_author"/> <meta content="Leiden University Medical Center" name="citation_author_institution"/> <meta content="E.J.van_Zuuren@lumc.nl" name="citation_author_email"/> <meta content="Zbys Fedorowicz" name="citation_author"/> <meta content="Veritas Health Sciences Consultancy Ltd" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="12" name="citation_issue"/> <meta content="10.1002/14651858.CD010155.pub3" name="citation_doi"/> <meta content="2015" name="citation_date"/> <meta content="2015/12/18" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010155.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010155.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010155.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Anemia, Sickle Cell [*complications]; Anticoagulants [*therapeutic use]; Dalteparin [*therapeutic use]; Heparin, Low-Molecular-Weight [*therapeutic use]; Pain Measurement; Peripheral Vascular Diseases [*drug therapy, etiology]; Randomized Controlled Trials as Topic; Tinzaparin" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010155.pub3&amp;doi=10.1002/14651858.CD010155.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010155.pub3&amp;doi=10.1002/14651858.CD010155.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010155.pub3&amp;doi=10.1002/14651858.CD010155.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010155.pub3&amp;doi=10.1002/14651858.CD010155.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010155.pub3&amp;doi=10.1002/14651858.CD010155.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010155.pub3&amp;doi=10.1002/14651858.CD010155.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010155.pub3&amp;doi=10.1002/14651858.CD010155.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010155.pub3&amp;doi=10.1002/14651858.CD010155.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010155.pub3&amp;doi=10.1002/14651858.CD010155.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010155.pub3&amp;doi=10.1002/14651858.CD010155.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010155.pub3&amp;doi=10.1002/14651858.CD010155.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010155.pub3&amp;doi=10.1002/14651858.CD010155.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010155.pub3&amp;doi=10.1002/14651858.CD010155.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010155.pub3&amp;doi=10.1002/14651858.CD010155.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010155.pub3&amp;doi=10.1002/14651858.CD010155.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010155.pub3&amp;doi=10.1002/14651858.CD010155.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010155.pub3&amp;doi=10.1002/14651858.CD010155.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010155.pub3&amp;doi=10.1002/14651858.CD010155.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010155.pub3&amp;doi=10.1002/14651858.CD010155.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010155.pub3&amp;doi=10.1002/14651858.CD010155.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010155.pub3&amp;doi=10.1002/14651858.CD010155.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010155.pub3&amp;doi=10.1002/14651858.CD010155.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010155.pub3&amp;doi=10.1002/14651858.CD010155.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="cdmLYOAV";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD010155\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD010155\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010155\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010155\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","fa","ms"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD010155.pub3",title:"Low\\u2010molecular\\u2010weight heparins for managing vaso\\u2010occlusive crises in people with sickle cell disease",firstPublishedDate:"Dec 18, 2015 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Cystic Fibrosis and Genetic Disorders Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=cdmLYOAV&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010155.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD010155.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD010155.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD010155.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010155.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD010155.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD010155.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD010155.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD010155.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD010155.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD010155.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD010155.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD010155.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD010155.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>1562 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD010155.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010155.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010155.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010155.pub3/full#CD010155-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010155.pub3/full#CD010155-sec-0090"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010155.pub3/full#CD010155-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010155.pub3/full#CD010155-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010155.pub3/full#CD010155-sec-0017"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010155.pub3/full#CD010155-sec-0018"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010155.pub3/full#CD010155-sec-0041"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010155.pub3/full#CD010155-sec-0079"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD010155.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010155.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010155.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010155.pub3/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD010155.pub3/media/CDSR/CD010155/table_n/CD010155StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD010155.pub3/media/CDSR/CD010155/table_n/CD010155StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010155.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010155.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010155.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD010155.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD010155.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD010155.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2015 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD010155.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Low‐molecular‐weight heparins for managing vaso‐occlusive crises in people with sickle cell disease </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010155.pub3/information#CD010155-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Esther J van Zuuren</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010155.pub3/information#CD010155-cr-0005">Zbys Fedorowicz</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD010155.pub3/information/en#CD010155-sec-0098">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 18 December 2015 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD010155.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD010155.pub3">https://doi.org/10.1002/14651858.CD010155.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD010155-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD010155-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD010155-abs-0008">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD010155-abs-0005">فارسی</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD010155-abs-0003">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD010155-abs-0001" lang="en"> <section id="CD010155-sec-0001"> <h3 class="title" id="CD010155-sec-0001">Background</h3> <p>Sickle cell disease is one of the most common and severe genetic disorders in the world. It can be broadly divided into two distinct clinical phenotypes characterized by either haemolysis or vaso‐occlusion. Pain is the most prominent symptom of vaso‐occlusion, and hypercoagulability is a well‐established pathogenic phenomenon in people with sickle cell disease. Low‐molecular‐weight heparins might control this hypercoagulable state through their anticoagulant effect. This is an update of a previously published version of this review. </p> </section> <section id="CD010155-sec-0002"> <h3 class="title" id="CD010155-sec-0002">Objectives</h3> <p>To assess the effects of low‐molecular‐weight heparins for managing vaso‐occlusive crises in people with sickle cell disease. </p> </section> <section id="CD010155-sec-0003"> <h3 class="title" id="CD010155-sec-0003">Search methods</h3> <p>We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group Haemoglobinopathies Trials Register comprising references identified from comprehensive electronic database searches. We also searched abstract books of conference proceedings and several online trials registries for ongoing trials. </p> <p>Date of the last search of the Cochrane Cystic Fibrosis and Genetic Disorders Group Haemoglobinopathies Trials Register: 28 September 2015. </p> </section> <section id="CD010155-sec-0004"> <h3 class="title" id="CD010155-sec-0004">Selection criteria</h3> <p>Randomised controlled clinical trials and controlled clinical trials that assessed the effects of low‐molecular‐weight heparins in the management of vaso‐occlusive crises in people with sickle cell disease. </p> </section> <section id="CD010155-sec-0005"> <h3 class="title" id="CD010155-sec-0005">Data collection and analysis</h3> <p>Study selection, data extraction, assessment of risk of bias and analyses were carried out independently by the two review authors. </p> </section> <section id="CD010155-sec-0006"> <h3 class="title" id="CD010155-sec-0006">Main results</h3> <p>Two studies comprising 287 participants were included. One study (with an overall unclear to high risk of bias) involved 253 participants and the quality of the evidence for most outcomes was very low. This study, reported that pain severity at day two and day three was lower in the tinzaparin group than in the placebo group (P &lt; 0.01, analysis of variance (ANOVA)) and additionally at day 4 (P &lt; 0.05 (ANOVA)). Thus tinzaparin resulted in more rapid resolution of pain, as measured with a numerical pain scale. The mean difference in duration of painful crises was statistically significant at ‐1.78 days in favour of the tinzaparin group (95% confidence interval ‐1.94 to ‐1.62). Participants treated with tinzaparin had statistically significantly fewer hospitalisation days than participants in the group treated with placebo, with a mean difference of ‐4.98 days (95% confidence interval ‐5.48 to ‐4.48). Two minor bleeding events were reported as adverse events in the tinzaparin group, and none were reported in the placebo group. The second study (unclear risk of bias) including 34 participants and was a conference abstract with limited data and only addressed one of the predefined outcomes of the review; i.e. pain intensity. After one day pain intensity reduced more, as reported on a visual analogue scale, in the dalteparin group than in the placebo group, mean difference ‐1.30 (95% confidence interval ‐1.60 to ‐1.00), with the quality of evidence rated very low. The most important reasons for downgrading the quality of evidence were serious risk of bias and imprecision (due to low sample size or low occurrence of events). </p> </section> <section id="CD010155-sec-0007"> <h3 class="title" id="CD010155-sec-0007">Authors' conclusions</h3> <p>Based on the results of two studies, evidence is incomplete to support or refute the effectiveness of low‐molecular‐weight heparins in people with sickle cell disease. Vaso‐occlusive crises are extremely debilitating for sufferers of sickle cell disease; therefore well‐designed placebo‐controlled studies with other types of low‐molecular‐weight heparins, and in participants with different genotypes of sickle cell disease, still need to be carried out to confirm or dismiss the results of this single study. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD010155-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD010155-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD010155-abs-0009">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD010155-abs-0006">فارسی</a> </li> <li class="section-language"> <a class="" href="full/ms#CD010155-abs-0007">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD010155-abs-0004">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD010155-abs-0002" lang="en"> <h3>Low‐molecular‐weight heparins for pain caused by obstruction of blood vessels in people with sickle cell disease </h3> <p><b>Review question</b> </p> <p>We reviewed the evidence about the effects of low‐molecular‐weight heparins in managing vaso‐occlusive crises in people with sickle cell disease<i>.</i> This is an update of a previously published version of this review. </p> <p><b>Background</b> </p> <p>Sickle cell disease is one of the most common and severe genetic blood disorders in the world. As the result of a change in the haemoglobin gene, red blood cells are transformed into cells with a sickle shape. This sickling of red blood cells results in various complications, amongst which are vaso‐occlusive crises. In a vaso‐occlusive crisis, the sickled red blood cells tend to clot together and block blood flow,which leads to pain in the organ involved. The pain can be very debilitating and often requires administration of morphine. Medication that prevents blood from clotting in the vessels might represent a useful contribution to existing treatment options for vaso‐occlusive crises. </p> <p><b>Search date</b> </p> <p>The evidence is current to: 28 September 2015.</p> <p><b>Study characteristics</b> </p> <p>The review included two studies that lasted seven days with a total of 287 people. One study involved 253 people (aged approximately 22 years) with sickle cell disease and compared tinzaparin with placebo and people were selected for one treatment or the other randomly. The other study was smaller with 34 participants (aged approximately 27 years) and compared dalteparin versus placebo. </p> <p><b>Key results</b> </p> <p>Tinzaparin reduced the number of days spent in hospital and reduced the pain (and the intensity of the pain) more rapidly. Two minor bleedings were reported in the tinzaparin group versus none in the placebo group. The data regarding the effectiveness of dalteparin were very limited and only addressed pain intensity, being more reduced by treatment with dalteparin than by placebo. These data are not sufficient to support the conclusion that low‐molecular‐weight heparins are effective in the treatment of vaso‐occlusive crises in people with sickle cell disease. Additional studies with different types of low‐molecular‐weight heparin used in different forms of sickle cell disease, are necessary to confirm or dismiss the results of this single study. Vaso‐occlusive crises can be extremely debilitating and can have a significant impact on quality of life; therefore it is important to know whether low‐molecular‐weight heparins might serve as a useful treatment option with few side effects. </p> <p><b>Quality of the evidence</b> </p> <p>The quality of the evidence for the majority of outcomes was very low, this had mainly to do with risk of bias of the studies (e.g. method of blinding unclear) or with small sample size of the studies. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD010155-sec-0090" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD010155-sec-0090"></div> <h3 class="title" id="CD010155-sec-0091">Implications for practice</h3> <section id="CD010155-sec-0091"> <p>Current recommendations and practices for the management of vaso‐occlusive crises in people with SCD continue to be largely based on clinicians' judgement. However, the results of this review demonstrate that at present, there is very low quality evidence to support reliable clinical decision making regarding the use of LMWHs in patients with SCD. </p> </section> <h3 class="title" id="CD010155-sec-0092">Implications for research</h3> <section id="CD010155-sec-0092"> <p>This review highlights the need for further randomised placebo‐controlled trials to evaluate the effects of LMWHs in the management of vaso‐occlusive crises in people with SCD, which can ultimately provide reliable evidence to help inform clinical decision making. </p> <p>Studies with other types of LMWHs, as well as in participants with different genotypes of SCD, still need to be carried out to confirm or dismiss the results reported by this single study. </p> <p>Any future RCTs must be well designed, well conducted and adequately delivered with subsequent reporting, including high‐quality descriptions of all aspects of methodology. Reporting should conform to the Consolidated Standards of Reporting Trials (CONSORT) statement (<a href="http://www.consort-statement.org/" target="_blank">http://www.consort-statement.org/</a>), which will enable appraisal and interpretation of results, as well as accurate judgements to be made about the risk of bias and the overall quality of the evidence. </p> <p>Although it is uncertain whether reported quality mirrors actual study conduct, it is noteworthy that studies with unclear methodology have been shown to produce biased estimates of treatment effects (<a href="./references#CD010155-bbs2-0036" title="SchulzKF , ChalmersI , HayesRJ , AltmanDG . Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA1995;273(5):408-12.">Schulz 1995</a>). </p> <p>For further research recommendations based on the EPICOT (evidence, population, intervention, comparison, outcomes and time) format (<a href="./references#CD010155-bbs2-0010" title="BrownP , BrunnhuberK , ChalkidouK , ChalmersI , ClarkeM , FentonM , et al. How to formulate research recommendations. BMJ2006;333(7572):804-6.">Brown 2006</a>), see an additional table (<a href="#CD010155-tbl-0006">Table 4</a>). </p> </section> <div class="table" id="CD010155-tbl-0006"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Research recommendations based on a gap in the evidence of the effects of low‐molecular‐weight heparins for managing vaso‐occlusive crises in people with sickle cell disease</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Core elements</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Issues to consider</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Status of research for this review</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Evidence (E)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>What is the current state of the evidence?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>This systematic review identified one RCT, which provided insufficient high‐level evidence of the efficacy and safety of LMWH for managing vaso‐occlusive crises in people with SCD. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Population (P)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Diagnosis, disease stage, co‐morbidity, risk factors, gender, age, ethnic group, specific inclusion or exclusion criteria, clinical setting </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Inclusion criteria</b> </p> <p> <ul id="CD010155-list-0019"> <li> <p>Participants with sickle cell disease (all different genotypes).</p> </li> <li> <p>Painful vaso‐occlusive crisis severe enough to require narcotic analgesia.</p> </li> </ul> </p> <p><b>Exclusion criteria</b> </p> <p> <ul id="CD010155-list-0020"> <li> <p>Contraindication to LMWH.</p> </li> <li> <p>Pregnancy.</p> </li> <li> <p>Low platelet counts (&lt; 100,000/dl) or impaired haemostasis on admission in the form of INR &gt; 1.4 or prolonged APTT &gt; 5 seconds of the hospital normal range. </p> </li> <li> <p>History of CVA.</p> </li> <li> <p>Current aplasia.</p> </li> <li> <p>Acute chest syndrome.</p> </li> <li> <p>Exchange transfusion.</p> </li> <li> <p>Sequestration.</p> </li> <li> <p>Anticoagulant therapy for other etiology.</p> </li> <li> <p>Patients with painful crises within the month before this admission.</p> </li> <li> <p>Women on hormonal contraception.</p> </li> <li> <p>History of painful crisis within the preceding month.</p> </li> <li> <p>Other vascular complications of sickle cell disease (such as prior stroke, current aplasia, acute chest pain). </p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intervention (I)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Type, frequency, dose, duration, prognostic factor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The study duration should be 1 ‐ 2 weeks to assess a low‐molecular‐weight heparin. Concomitant pain medications allowed for ethical reasons but should be similarly available in both treatment arms. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Comparison (C)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Type, frequency, dose, duration, prognostic factor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No treatment or placebo treatment. Concomitant pain medications allowed for ethical reasons but should be similarly available in both treatment arms. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Outcome (O)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Which clinical or patient‐related outcomes will the researcher need to measure, improve, influence, or accomplish? Which methods of </p> <p>measurement should be used?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD010155-list-0021"> <li> <p>Pain: duration and intensity (assessed with a validated patient‐reported outcomes instrument either generic or SCD specific). </p> </li> </ul> <ul id="CD010155-list-0022"> <li> <p>Requirement for opiate treatment (dose, type and frequency).</p> </li> <li> <p>Number of serious complications of SCD (e.g. stroke, acute chest syndrome, infection, acute splenic sequestration). </p> </li> <li> <p>Number of other sickle‐related events (e.g. priapism, leg ulceration).</p> </li> <li> <p>Quality of life (e.g. absence from school, lost time at work, mobility) as assessed by any validated questionnaire, either generic or SCD specific. </p> </li> <li> <p>Hospitalisation (number and duration).</p> </li> <li> <p>Participant satisfaction with the medication assessed by any appropriate and validated questionnaire (either generic or SCD specific). </p> </li> <li> <p>Adverse events associated with the use of anticoagulants (e.g. bleeding).</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Time stamp (T)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Date of literature search or recommendation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 January 2013.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study type</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>What is the most appropriate study design to address the proposed question?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD010155-list-0023"> <li> <p>Randomised controlled trial (adequately powered / multi‐centred).</p> </li> <li> <p>Method: concealment of allocation sequence.</p> </li> <li> <p>Blinding: blinding of participants, trialists and outcome assessors.</p> </li> <li> <p>Setting: hospital / university.</p> </li> </ul> </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>APTT: activated partial thromboplastin time<br/>CVA: cerebral vascular accident<br/>INR: international normalized ratio<br/>LMWH: low‐molecular‐weight heparins<br/>RCT: randomised controlled trial<br/>SCD: sickle cell disease </p> </div> </div> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD010155-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD010155-sec-0008"></div> <div class="table" id="CD010155-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Tinzaparin compared to placebo for people with sickle cell disease</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Tinzaparin compared to placebo for people with sickle cell disease</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population</b> : people with sickle cell disease<br/><b>Settings</b> : hospitals<br/><b>Intervention</b> : tinzaparin<br/><b>Comparison</b>: placebo </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No of Participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Placebo</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Tinzaparin</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pain intensity</b><br/>Numeric pain scale<br/>Follow up: mean 7 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment<sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>253<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low</b><sup>2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The authors reported at D2 and D3, the pain severity score was lower in the tinzaparin group than in the placebo group (P &lt; 0.01), to that at D4 (P &lt; 0.05) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pain duration</b><br/>Scale from: 1 to 7.<br/>Follow up: mean 7 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean pain duration in the control group was<br/><b>4.35 days</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean pain duration in the intervention group was<br/><b>1.78 lower</b><br/>(1.94 to 1.62 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>253<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low</b><sup>2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The duration of painful crises was almost 2 days shorter in the tinzaparin group</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>The requirement for opiate treatment</b><br/>Follow up: mean 7 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>253<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low</b><sup>2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This outcome was inadequately reported, only that during the study all participants received standard analgesia therapy consisting of morphine at 1 mg/h </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of serious complications of SCD</b> ‐ not measured </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not assessed</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of other sickle‐related events</b> ‐ not measured </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not assessed</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life (e.g. absence from school, lost time at work, mobility) as assessed by any validated questionnaire either generic or SCD specific)</b> ‐ not measured </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not assessed</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Hospitalisation (number and duration)</b><br/>Scale from: 0 to 12.<br/>Follow up: mean 7 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean hospitalisation (number and duration) in the control group was<br/><b>12.06 days</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean hospitalisation (number and duration) in the intervention group was<br/><b>4.98 lower</b><br/>(5.48 to 4.48 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>253<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low</b><sup>2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants treated with tinzaparin had almost 5 hospitalisation days less compared with those in the group treated with placebo </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participant satisfaction with the medication assessed by any appropriate and validated questionnaire (either generic or SCD specific)</b> ‐ not measured </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not assessed</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events associated with the use of anticoagulants (e.g. bleeding)</b><br/>Follow‐up: mean 7 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 4.96</b> <br/>(0.24 to 102.31) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>253<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>4,5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Two minor bleeding events were reported in the tinzaparin group compared with none in the placebo group </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI</b> : confidence interval; <b>RR</b>: risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality</b> : further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality</b> : further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality</b>: we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> No precise data were reported.<br/><sup>2</sup> Downgraded two levels for very serious risk of bias. Sequence generation is unclear as well as allocation concealment and measurements to blind the investigators and participants. A potential conflict of interest cannot be excluded as one of the investigators is an employee of the manufacturer of tinzaparin. The NMS scale is not a validated tool for pain assessment.<br/><sup>3</sup> Downgraded one level for serious imprecision. Total population size is less than 400<br/><sup>4</sup> We did not downgrade for risk of bias for this outcome<br/><sup>5</sup> Downgraded two levels for very serious imprecision due to very wide confidence intervals caused by low occurrence of events </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD010155-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Dalteparin compared to placebo for people with sickle cell disease</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Dalteparin compared to placebo for people with sickle cell disease</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with people with sickle cell disease<br/><b>Settings:</b> hospital<br/><b>Intervention:</b> dalteparin<br/><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No of Participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Placebo</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Dalteparin</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pain intensity</b><br/>VAS 0‐10. Scale from: 0 to 10.<br/>Follow‐up: mean 7 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean pain intensity in the control group was<br/><b>‐ 0.3</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean pain intensity in the intervention group was<br/><b>1.30 lower</b><br/>(1.60 to 1.00 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants in the dalteparin group had less pain than the participants in the placebo group after one day. After 3 days there was a 41% loss to follow‐up making data less usable </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pain duration</b> ‐ not measured </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not assessed</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>The requirement for opiate treatment</b> ‐ not measured </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not assessed</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of serious complications of SCD</b> ‐ not measured </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not assessed</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of other sickle‐related events</b> ‐ not measured </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not assessed</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life (e.g. absence from school, lost time at work, mobility) as assessed by any validated questionnaire either generic or SCD specific)</b> ‐ not measured </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not assessed</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Hospitalisation (number and duration)</b> ‐ not measured </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not assessed</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participant satisfaction with the medication assessed by any appropriate and validated questionnaire (either generic or SCD specific)</b> ‐ not measured </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not assessed</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events associated with the use of anticoagulants (e.g. bleeding)</b> ‐ not measured </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not assessed</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI</b>: confidence interval; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality</b> : further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality</b> : further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality</b> : further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality</b>: we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded one level for serious risk of bias as almost all domains were judged as unclear<br/><sup>2</sup> Downgraded two levels for serious imprecision. Very small sample size </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD010155-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD010155-sec-0009"></div> <p>Please refer to an additional table for definitions of clinical terms (<a href="#CD010155-tbl-0003">Table 1</a>). </p> <div class="table" id="CD010155-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Glossary of Terms</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Term</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Definition</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Anticoagulant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>A substance that prevents coagulation (clotting) of blood.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Genotype</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The genotype of an individual is the set of inherited instructions carried within its genetic code. Not all organisms with the same genotype look or act the same way because appearance and behaviour are modified by environmental and developmental conditions. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Haemoglobin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The iron‐containing oxygen‐transport metalloprotein in the red blood cells. Haemoglobin in the blood carries oxygen from the respiratory organs (lungs) to the rest of the body. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Heterozygous</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>A cell is said to be heterozygous when it contains two different alleles of a gene.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Homozygosity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>A cell is said to be homozygous for a particular gene when identical alleles of the gene are present on both homologous chromosomes. The individual is called a <i>homozygote</i>. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lyse</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>To destroy or dissolve cells.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Necrosis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The premature death of cells in living tissue.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Phenotype</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The composite of an individual's observable characteristics or traits, such as its morphology, development, biochemical or physiological properties and behaviour. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P‐selectin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>A cell adhesion molecule (CAM) on the surfaces of activated endothelial cells (thin layer of cells that lines the interior surface of blood vessels), which line the inner surface of blood vessels, and activated platelets (thin layer of cells that lines the interior surface of blood vessels). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Polarize</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Aggregate.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tumour necrosis factor‐α</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>A cytokine; cell‐signalling (transmitting information between cells) protein involved in systemic inflammation; a member of a group of cytokines that stimulate the acute phase reaction. </p> </td> </tr> </tbody> </table> </div> <section id="CD010155-sec-0010"> <h3 class="title" id="CD010155-sec-0010">Description of the condition</h3> <section id="CD010155-sec-0011"> <h4 class="title">Definition and clinical features</h4> <p>Sickle cell disease (SCD) is one of the most common and severe genetic disorders in the world. The term SCD covers several common genotypes (<a href="./references#CD010155-bbs2-0034" title="ReesDC , WilliamsTN , GladwinMT . Sickle-cell disease. Lancet2010;376(9757):2018-31. [PMID: PMID: 21131035]">Rees 2010</a>; <a href="./references#CD010155-bbs2-0039" title="SteinbergMH . In the Clinic. Sickle cell disease. Annals of Internal Medicine2011;155(5):ITC31-15. [PMID: 21893620]">Steinberg 2011</a>). </p> <p> <ul id="CD010155-list-0001"> <li> <p>Sickle cell anaemia: homozygosity for the sickle haemoglobin gene (<i>HbS</i> ). This is the most prevalent form of SCD and is caused by inheritance from both parents of an <i>HbS</i> gene. </p> </li> <li> <p>Sickle cell‐haemoglobin C (HbSC) disease: compound heterozygosity for <i>HbS</i> and haemoglobin C (<i>HbC</i> ) genes. This second most common type of SCD is caused by inheritance of one sickle cell gene from one parent and another abnormal haemoglobin gene (<i>HbC</i>) from the other. </p> </li> <li> <p>HbS–β‐thalassaemia: compound heterozygosity for HbS and a β<sup>0‐</sup> or β<sup>+</sup>‐thalassaemia gene (Sβ<sup>0</sup>, Sβ<sup>+</sup>). The third major type of SCD, caused by inheritance of one sickle cell gene from one parent and one β<sup>0‐</sup> or β<sup>+</sup>‐thalassaemia gene from the other. </p> </li> <li> <p>Other double heterozygous conditions such as haemoglobin SD disease (HbSD), haemoglobin SE disease (HbSE), etc. </p> </li> </ul> </p> <p>Homozygous sickle cell (SS) disease and sickle cell/β<sup>0</sup>‐thalassaemia are generally considered the more severe forms of the disease, whilst HbSC disease and sickle cell β<sup>+‐</sup>thalassaemia tend to be milder (<a href="./references#CD010155-bbs2-0003" title="Al HajeriA , SerjeantGR , FedorowiczZ . Inhaled nitric oxide for acute chest syndrome in people with sickle cell disease. Cochrane Database of Systematic Reviews2008, Issue 1. Art. No: CD006957. [DOI: 10.1002/14651858.CD006957]">Al Hajeri 2008</a>). Sickle cell trait (heterozygotes who carry one HbS allele and one normal adult haemoglobin (HbA) allele) is clinically benign and should not be considered a disease (<a href="./references#CD010155-bbs2-0039" title="SteinbergMH . In the Clinic. Sickle cell disease. Annals of Internal Medicine2011;155(5):ITC31-15. [PMID: 21893620]">Steinberg 2011</a>). However, recent literature reports point to associations with serious conditions such as exercise‐related sudden death, exertional rhabdomyolysis, venous thromboembolism and renal complications, suggesting that sickle cell trait is not as benign as it was previously considered to be (<a href="./references#CD010155-bbs2-0005" title="AustinH , KeyNS , BensonJM , LallyC , DowlingNF , WhitsettC , et al. Sickle cell trait and the risk of venous thromboembolism among blacks. Blood2007;110(3):908-12. [PMID: PMID: 17409269]">Austin 2007</a>; <a href="./references#CD010155-bbs2-0006" title="AustinH , LallyC , BensonJM , WhitsettC , HooperWC , KeyNS . Hormonal contraception, sickle cell trait, and risk for venous thromboembolism among African American women. American Journal of Obstetrics and Gynecology2009;200(6):620.e1-3. [PMID: PMID: 19306959]">Austin 2009</a>; <a href="./references#CD010155-bbs2-0018" title="GoldsmithJC , BonhamVL , JoinerCH , KatoGJ , NoonanAS , SteinbergMH . Framing the research agenda for sickle cell trait: building on the current understanding of clinical events and their potential implications. American Journal of Hematology2012;87(3):340-6. [PMID: PMID: 22307997]">Goldsmith 2012</a>; <a href="./references#CD010155-bbs2-0031" title="KeyNS , DerebailVK . Sickle-cell trait: novel clinical significance. Hematology/ the Education Program of the American Society of Hematology2010;2010:418-22. [PMID: PMID: 21239829]">Key 2010</a>). </p> <p>Individual heterogeneity between people with SCD makes clinical manifestations of the diseases highly variable in frequency and severity, ranging from completely asymptomatic cases to very severe forms. However, most patients (about 70%) have a moderate phenotype (<a href="./references#CD010155-bbs2-0028" title="InatiA . Recent advances in improving the management of sickle cell disease. Blood Reviews2009;23 Suppl 1:S9-13. [PMID: PMID: 20116638]">Inati 2009</a>). </p> <p>Sickle cell disease can be broadly divided into distinct clinical phenotypes characterised by either haemolysis or vaso‐occlusion (<a href="./references#CD010155-bbs2-0007" title="BallasSK , LieffS , BenjaminLJ , DampierCD , HeeneyMM , HoppeC , et al. Definitions of the phenotypic manifestations of sickle cell disease. American Journal of Hematology2010;85(1):6-13. [PMID: PMID:19902523]">Ballas 2010</a>; <a href="./references#CD010155-bbs2-0008" title="BallasSK , KesenMG , GoldbergMF , LuttyGA , DampierC , OsunkwoI , et al. Beyond the definitions of the phenotypic complications of sickle cell disease: An update on management. The Scientific World Journal2012;2012:949535. [DOI: 10.1100/2012/949535]">Ballas 2012</a>; <a href="./references#CD010155-bbs2-0028" title="InatiA . Recent advances in improving the management of sickle cell disease. Blood Reviews2009;23 Suppl 1:S9-13. [PMID: PMID: 20116638]">Inati 2009</a>). During haemolysis the red blood cells lyse prematurely and the content of the cells, that is, the haemoglobin, is released into the surrounding fluid; during vaso‐occlusion the sickled red blood cells clump together, obstructing blood flow and damaging corresponding tissues and organs. Vaso‐occlusion leads to both acute and chronic complications (<a href="./references#CD010155-bbs2-0033" title="MousaSA , Al MomenA , Al SayeghF , Al JaouniS , NasrullahZ , Al SaeedH , et al. Management of painful vaso-occlusive crisis of sickle-cell anemia: consensus opinion. Clinical and Applied Thrombosis/Haemostasis2010;16(4):365-76. [PMID: PMID: 20530056]">Mousa 2010</a>). Clinical manifestations of vaso‐occlusion include acute episodes of severe pain (crises); acute chest syndrome (a life‐threatening pneumonia‐like illness); increased infections; joint necrosis; stroke; spontaneous abortion; and multi‐organ failure (<a href="./references#CD010155-bbs2-0007" title="BallasSK , LieffS , BenjaminLJ , DampierCD , HeeneyMM , HoppeC , et al. Definitions of the phenotypic manifestations of sickle cell disease. American Journal of Hematology2010;85(1):6-13. [PMID: PMID:19902523]">Ballas 2010</a>; <a href="./references#CD010155-bbs2-0008" title="BallasSK , KesenMG , GoldbergMF , LuttyGA , DampierC , OsunkwoI , et al. Beyond the definitions of the phenotypic complications of sickle cell disease: An update on management. The Scientific World Journal2012;2012:949535. [DOI: 10.1100/2012/949535]">Ballas 2012</a>; <a href="./references#CD010155-bbs2-0009" title="BallasSK . Sickle cell anemia. http://pier.acponline.org/physicians/diseases/d905/d905.html (accessed 28 February 2013):1-93.">Ballas 2013</a>; <a href="./references#CD010155-bbs2-0028" title="InatiA . Recent advances in improving the management of sickle cell disease. Blood Reviews2009;23 Suppl 1:S9-13. [PMID: PMID: 20116638]">Inati 2009</a>; <a href="./references#CD010155-bbs2-0033" title="MousaSA , Al MomenA , Al SayeghF , Al JaouniS , NasrullahZ , Al SaeedH , et al. Management of painful vaso-occlusive crisis of sickle-cell anemia: consensus opinion. Clinical and Applied Thrombosis/Haemostasis2010;16(4):365-76. [PMID: PMID: 20530056]">Mousa 2010</a>; <a href="./references#CD010155-bbs2-0038" title="SteinbergMH . Management of sickle cell disease. New England Journal of Medicine1999;340(13):1021-30. [PMID: PMID: 10099145]">Steinberg 1999</a>). Chronic haemolysis manifests clinically as anaemia, cholelithiasis (presence of gall stones), pulmonary hypertension, priapism (painful persistent erections), leg ulceration, sudden death, and possibly stroke (<a href="./references#CD010155-bbs2-0017" title="GladwinMT , SachdevV . Cardiovascular abnormalities in sickle cell disease. Journal of the American College of Cardiology2012;59(13):1123-33. [PMID: PMID:22440212]">Gladwin 2012</a>; <a href="./references#CD010155-bbs2-0029" title="InatiA , ChabtiniL , MounayarM , TaherA . Current understanding in the management of sickle cell disease. Hemoglobin2009;33 Suppl 1:S107-15. [PMID: PMID: 20001613]">Inati 2009b</a>). However, the severity of the clinical manifestations depends on the degree of haemolysis, and those with less haemolysis are predicted to have pain crises, acute chest syndrome, and osteonecrosis (<a href="./references#CD010155-bbs2-0011" title="BunnHF , NathanDG , DoverGJ , HebbelRP , PlattOS , RosseWF , et al. Pulmonary hypertension and nitric oxide depletion in sickle cell disease. Blood2010;116(5):687-92. [PMID: PMID:20395414]">Bunn 2010</a>). According to Bunn and colleagues, pulmonary hypertension is usually minor and is confounded by several co‐morbid conditions including high cardiac output, pulmonary vascular inflammation and occlusion (thrombosis in situ, fat embolism), as well as left ventricular failure (<a href="./references#CD010155-bbs2-0011" title="BunnHF , NathanDG , DoverGJ , HebbelRP , PlattOS , RosseWF , et al. Pulmonary hypertension and nitric oxide depletion in sickle cell disease. Blood2010;116(5):687-92. [PMID: PMID:20395414]">Bunn 2010</a>). A comprehensive overview of clinical signs and symptoms is provided in a article by <a href="./references#CD010155-bbs2-0007" title="BallasSK , LieffS , BenjaminLJ , DampierCD , HeeneyMM , HoppeC , et al. Definitions of the phenotypic manifestations of sickle cell disease. American Journal of Hematology2010;85(1):6-13. [PMID: PMID:19902523]">Ballas 2010</a>, in which clinical manifestations are divided into three groups; haemolytic anaemia and its sequelae, pain syndromes and related issues and complications in major organs and related co‐morbidities. Morbidity and mortality in people with SCD mainly result from tissue infarction (tissue death due to oxygen shortage) secondary to obstruction of the small blood vessels by sickle cells (<a href="./references#CD010155-bbs2-0013" title="DaviesEG , HirstC , LottenbergR , DowerN . Pneumococcal vaccines for sickle cell disease. Cochrane Database of Systematic Reviews2012, Issue 2. Art. No: CD003885. [DOI: 10.1002/14651858.CD003885.pub2]">Davies 2012</a>). </p> </section> <section id="CD010155-sec-0012"> <h4 class="title">Symptoms</h4> <p>Pain is the hallmark of SCD (<a href="./references#CD010155-bbs2-0009" title="BallasSK . Sickle cell anemia. http://pier.acponline.org/physicians/diseases/d905/d905.html (accessed 28 February 2013):1-93.">Ballas 2013</a>; <a href="./references#CD010155-bbs2-0016" title="deMontalembertM . Management of sickle cell disease. BMJ2008;337:a1397. [PMID: PMID: 18779222]">de Montalembert 2008</a>; <a href="./references#CD010155-bbs2-0039" title="SteinbergMH . In the Clinic. Sickle cell disease. Annals of Internal Medicine2011;155(5):ITC31-15. [PMID: 21893620]">Steinberg 2011</a>). It can be acute or chronic and most often is located in joints, extremities, back or chest, but pain can occur anywhere and can last several days or weeks, or longer (<a href="./references#CD010155-bbs2-0016" title="deMontalembertM . Management of sickle cell disease. BMJ2008;337:a1397. [PMID: PMID: 18779222]">de Montalembert 2008</a>; <a href="./references#CD010155-bbs2-0039" title="SteinbergMH . In the Clinic. Sickle cell disease. Annals of Internal Medicine2011;155(5):ITC31-15. [PMID: 21893620]">Steinberg 2011</a>). The frequency and severity of painful episodes vary widely within and between individual patients (<a href="./references#CD010155-bbs2-0016" title="deMontalembertM . Management of sickle cell disease. BMJ2008;337:a1397. [PMID: PMID: 18779222]">de Montalembert 2008</a>; <a href="./references#CD010155-bbs2-0039" title="SteinbergMH . In the Clinic. Sickle cell disease. Annals of Internal Medicine2011;155(5):ITC31-15. [PMID: 21893620]">Steinberg 2011</a>). Acute chest syndrome is characterised by fever, cough, sputum production, tachypnoea (rapid breathing) and dyspnoea (breathing difficulties) and is the second most common reason for hospitalisation in this group of patients after pain (<a href="./references#CD010155-bbs2-0007" title="BallasSK , LieffS , BenjaminLJ , DampierCD , HeeneyMM , HoppeC , et al. Definitions of the phenotypic manifestations of sickle cell disease. American Journal of Hematology2010;85(1):6-13. [PMID: PMID:19902523]">Ballas 2010</a>; <a href="./references#CD010155-bbs2-0009" title="BallasSK . Sickle cell anemia. http://pier.acponline.org/physicians/diseases/d905/d905.html (accessed 28 February 2013):1-93.">Ballas 2013</a>; <a href="./references#CD010155-bbs2-0016" title="deMontalembertM . Management of sickle cell disease. BMJ2008;337:a1397. [PMID: PMID: 18779222]">de Montalembert 2008</a>; <a href="./references#CD010155-bbs2-0039" title="SteinbergMH . In the Clinic. Sickle cell disease. Annals of Internal Medicine2011;155(5):ITC31-15. [PMID: 21893620]">Steinberg 2011</a>). </p> <p>Patients are more susceptible to infection; in children the most prevalent agent is <i>Streptococcus pneumoniae</i>, and in adults gram‐negative organisms are more common (<a href="./references#CD010155-bbs2-0016" title="deMontalembertM . Management of sickle cell disease. BMJ2008;337:a1397. [PMID: PMID: 18779222]">de Montalembert 2008</a>; <a href="./references#CD010155-bbs2-0039" title="SteinbergMH . In the Clinic. Sickle cell disease. Annals of Internal Medicine2011;155(5):ITC31-15. [PMID: 21893620]">Steinberg 2011</a>). Fatigue and shortness of breath are symptoms of pulmonary hypertension, which is another frequent complication. Strokes occur in approximately 10% of children and adults with sickle cell anaemia but are much less common in other genotypes of the disease (<a href="./references#CD010155-bbs2-0028" title="InatiA . Recent advances in improving the management of sickle cell disease. Blood Reviews2009;23 Suppl 1:S9-13. [PMID: PMID: 20116638]">Inati 2009</a>; <a href="./references#CD010155-bbs2-0039" title="SteinbergMH . In the Clinic. Sickle cell disease. Annals of Internal Medicine2011;155(5):ITC31-15. [PMID: 21893620]">Steinberg 2011</a>) and can lead to cognitive impairment as a result of neurological changes. </p> <p>Anaemia manifests as fatigue, dizziness, headache, and cold hands and feet. Other complications associated with SCD include priapism in men leading to painful erections; leg ulcers, which can be both painful and disabling; sight problems due to retinopathy; and renal failure. But in fact all organs can be affected, resulting in organ‐specific symptoms and complications (<a href="./references#CD010155-bbs2-0007" title="BallasSK , LieffS , BenjaminLJ , DampierCD , HeeneyMM , HoppeC , et al. Definitions of the phenotypic manifestations of sickle cell disease. American Journal of Hematology2010;85(1):6-13. [PMID: PMID:19902523]">Ballas 2010</a>; <a href="./references#CD010155-bbs2-0008" title="BallasSK , KesenMG , GoldbergMF , LuttyGA , DampierC , OsunkwoI , et al. Beyond the definitions of the phenotypic complications of sickle cell disease: An update on management. The Scientific World Journal2012;2012:949535. [DOI: 10.1100/2012/949535]">Ballas 2012</a>; <a href="./references#CD010155-bbs2-0009" title="BallasSK . Sickle cell anemia. http://pier.acponline.org/physicians/diseases/d905/d905.html (accessed 28 February 2013):1-93.">Ballas 2013</a>; <a href="./references#CD010155-bbs2-0016" title="deMontalembertM . Management of sickle cell disease. BMJ2008;337:a1397. [PMID: PMID: 18779222]">de Montalembert 2008</a>; <a href="./references#CD010155-bbs2-0039" title="SteinbergMH . In the Clinic. Sickle cell disease. Annals of Internal Medicine2011;155(5):ITC31-15. [PMID: 21893620]">Steinberg 2011</a>). </p> </section> <section id="CD010155-sec-0013"> <h4 class="title">Epidemiology and causes</h4> <p>With estimates of approximately 300,000 babies born each year with documented SCD, this is one of the most common genetic inherited diseases worldwide (<a href="./references#CD010155-bbs2-0016" title="deMontalembertM . Management of sickle cell disease. BMJ2008;337:a1397. [PMID: PMID: 18779222]">de Montalembert 2008</a>; <a href="./references#CD010155-bbs2-0033" title="MousaSA , Al MomenA , Al SayeghF , Al JaouniS , NasrullahZ , Al SaeedH , et al. Management of painful vaso-occlusive crisis of sickle-cell anemia: consensus opinion. Clinical and Applied Thrombosis/Haemostasis2010;16(4):365-76. [PMID: PMID: 20530056]">Mousa 2010</a>; <a href="./references#CD010155-bbs2-0034" title="ReesDC , WilliamsTN , GladwinMT . Sickle-cell disease. Lancet2010;376(9757):2018-31. [PMID: PMID: 21131035]">Rees 2010</a>; <a href="./references#CD010155-bbs2-0040" title="World Health Organization. Sickle-cell anaemia. Report A59/9. Provisional agenda item 11.4. 59th World Health Assembly. https://apps.who.int/gb/ebwha/pdf_files/WHA59/A59_9-en.pdf (accessed 13 March 2012).">WHO 2006</a>). Prevalence is highest among people whose ancestors come from sub‐Saharan Africa, India, Saudi Arabia and Mediterranean countries (<a href="./references#CD010155-bbs2-0034" title="ReesDC , WilliamsTN , GladwinMT . Sickle-cell disease. Lancet2010;376(9757):2018-31. [PMID: PMID: 21131035]">Rees 2010</a>; <a href="./references#CD010155-bbs2-0040" title="World Health Organization. Sickle-cell anaemia. Report A59/9. Provisional agenda item 11.4. 59th World Health Assembly. https://apps.who.int/gb/ebwha/pdf_files/WHA59/A59_9-en.pdf (accessed 13 March 2012).">WHO 2006</a>), but in our increasingly multi‐ethnic world, the disease has become a global problem (<a href="./references#CD010155-bbs2-0016" title="deMontalembertM . Management of sickle cell disease. BMJ2008;337:a1397. [PMID: PMID: 18779222]">de Montalembert 2008</a>; <a href="./references#CD010155-bbs2-0039" title="SteinbergMH . In the Clinic. Sickle cell disease. Annals of Internal Medicine2011;155(5):ITC31-15. [PMID: 21893620]">Steinberg 2011</a>; <a href="./references#CD010155-bbs2-0040" title="World Health Organization. Sickle-cell anaemia. Report A59/9. Provisional agenda item 11.4. 59th World Health Assembly. https://apps.who.int/gb/ebwha/pdf_files/WHA59/A59_9-en.pdf (accessed 13 March 2012).">WHO 2006</a>).<br/><br/>Sickle cell disease is caused by inheritance from both parents of a mutation in the beta‐globin gene. As a result of this point mutation in the sixth position of the β‐globin chain, valine is substituted for glutamic acid, leading to the production of a defective form of haemoglobin (haemoglobin S (HbS)) (<a href="./references#CD010155-bbs2-0015" title="De FranceschiL , CappelliniMD , OlivieriO . Thrombosis and sickle cell disease. Seminars in Thrombosis and Hemostasis2011;37(3):226-36. [PMID: PMID: 21455857]">De Franceschi 2011</a>; <a href="./references#CD010155-bbs2-0029" title="InatiA , ChabtiniL , MounayarM , TaherA . Current understanding in the management of sickle cell disease. Hemoglobin2009;33 Suppl 1:S107-15. [PMID: PMID: 20001613]">Inati 2009b</a>; <a href="./references#CD010155-bbs2-0033" title="MousaSA , Al MomenA , Al SayeghF , Al JaouniS , NasrullahZ , Al SaeedH , et al. Management of painful vaso-occlusive crisis of sickle-cell anemia: consensus opinion. Clinical and Applied Thrombosis/Haemostasis2010;16(4):365-76. [PMID: PMID: 20530056]">Mousa 2010</a>). Upon deoxygenation, HbS polymerises to the sickle form with distorted, sickle‐shaped dehydrated red blood cells (<a href="./references#CD010155-bbs2-0029" title="InatiA , ChabtiniL , MounayarM , TaherA . Current understanding in the management of sickle cell disease. Hemoglobin2009;33 Suppl 1:S107-15. [PMID: PMID: 20001613]">Inati 2009b</a>). Sickle erythrocytes occlude blood vessels of all sizes (<a href="./references#CD010155-bbs2-0039" title="SteinbergMH . In the Clinic. Sickle cell disease. Annals of Internal Medicine2011;155(5):ITC31-15. [PMID: 21893620]">Steinberg 2011</a>), causing a spectrum of clinical manifestations, in addition to haemolysis and anaemia (<a href="./references#CD010155-bbs2-0033" title="MousaSA , Al MomenA , Al SayeghF , Al JaouniS , NasrullahZ , Al SaeedH , et al. Management of painful vaso-occlusive crisis of sickle-cell anemia: consensus opinion. Clinical and Applied Thrombosis/Haemostasis2010;16(4):365-76. [PMID: PMID: 20530056]">Mousa 2010</a>). It can cause severe pain crises and progressive organ damage to virtually every organ system in the body, and it is associated with a reduced life expectancy (<a href="./references#CD010155-bbs2-0033" title="MousaSA , Al MomenA , Al SayeghF , Al JaouniS , NasrullahZ , Al SaeedH , et al. Management of painful vaso-occlusive crisis of sickle-cell anemia: consensus opinion. Clinical and Applied Thrombosis/Haemostasis2010;16(4):365-76. [PMID: PMID: 20530056]">Mousa 2010</a>; <a href="./references#CD010155-bbs2-0034" title="ReesDC , WilliamsTN , GladwinMT . Sickle-cell disease. Lancet2010;376(9757):2018-31. [PMID: PMID: 21131035]">Rees 2010</a>; <a href="./references#CD010155-bbs2-0040" title="World Health Organization. Sickle-cell anaemia. Report A59/9. Provisional agenda item 11.4. 59th World Health Assembly. https://apps.who.int/gb/ebwha/pdf_files/WHA59/A59_9-en.pdf (accessed 13 March 2012).">WHO 2006</a>). </p> </section> </section> <section id="CD010155-sec-0014"> <h3 class="title" id="CD010155-sec-0014">Description of the intervention</h3> <p>Low‐molecular‐weight heparins (LMWHs) act through the antithrombin inhibition of Factor Xa more than Factor IIa (thrombin) and have greater bioavailability and longer duration of action than unfractionated heparin (<a href="./references#CD010155-bbs2-0027" title="HoySM , ScottLJ , PloskerGL . Tinzaparin sodium: a review of its use in the prevention and treatment of deep vein thrombosis and pulmonary embolism, and in the prevention of clotting in the extracorporeal circuit during haemodialysis. Drugs2010;70(10):1319-47. [PMID: PMID: 20568836]">Hoy 2010</a>) (see <a href="#CD010155-tbl-0004">Table 2</a> for the classes of anticoagulants). At a higher dose, LMWHs are used to treat active thrombotic diseases such as deep vein thromboses, pulmonary emboli, or both, and they are used at lower doses to prevent thrombosis. The LMWHs have a more predictable anticoagulant response than unfractionated heparin, allowing them to be administered in fixed, weight‐based dosages without routine laboratory monitoring, thus facilitating outpatient therapy (<a href="./references#CD010155-bbs2-0027" title="HoySM , ScottLJ , PloskerGL . Tinzaparin sodium: a review of its use in the prevention and treatment of deep vein thrombosis and pulmonary embolism, and in the prevention of clotting in the extracorporeal circuit during haemodialysis. Drugs2010;70(10):1319-47. [PMID: PMID: 20568836]">Hoy 2010</a>). Conducting a systematic review of the effectiveness and safety of LMWHs is warranted because hypercoagulability in SCD is a well‐established pathogenic phenomenon (<a href="./references#CD010155-bbs2-0004" title="AtagaKI , BrittainJE , DesaiP , MayR , JonesS , DelaneyJ , et al. Association of coagulation activation with clinical complications in sickle cell disease. Plos One2012;7(1):e29786. [PMID: PMID: 22253781]">Ataga 2012</a>). Several studies have suggested the use of tinzaparin (one of the commonly used LMWHs) to control the hypercoagulable state of SCD, but none have provided solid evidence to support or discourage the use of LMWHs (<a href="./references#CD010155-bbs2-0014" title="De FranceschiL . Pathophisiology of sickle cell disease and new drugs for the treatment. Mediterranean Journal of Hematology and Infectious Diseases2009;1(1):e2009024. [PMID: PMID:21415994]">De Franceschi 2009</a>; <a href="./references#CD010155-bbs2-0024" title="HiraniA , WeibelS , KaneGC . Acute chest syndrome and other pulmonary manifestations of sickle cell disease. Journal of Clinical Outcome Management2011;18(5):211-21.">Hirani 2011</a>; <a href="./references#CD010155-bbs2-0033" title="MousaSA , Al MomenA , Al SayeghF , Al JaouniS , NasrullahZ , Al SaeedH , et al. Management of painful vaso-occlusive crisis of sickle-cell anemia: consensus opinion. Clinical and Applied Thrombosis/Haemostasis2010;16(4):365-76. [PMID: PMID: 20530056]">Mousa 2010</a>; <a href="./references#CD010155-bbs2-0001" title="QariMH , AljaouniSK , AlardawiMS , FataniH , AlsayesFM , ZografosP , et al. Reduction of painful vaso-occlusive crisis of sickle cell anaemia by tinzaparin in a double-blind randomized trial. Thrombosis and Haemostasis2007;98(2):392-6. [PMID: PMID: 17721622]QariMH , MousaS , AlsaighMA , ZografosP , AljaouniSK , FataniH , et al. Tinzaparin in the management of painful vaso-occlusive crisis of sickle cell anaemia. Blood2005;106(11):Abstract no: 2340. ">Qari 2007</a>). </p> <div class="table" id="CD010155-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Classes of anticoagulants</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Coumarins (vitamin K antagonists)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ol id="CD010155-list-0002"> <li> <p>Warfarin.</p> </li> <li> <p>Acenocoumarol and phenprocoumon.</p> </li> <li> <p>Atromentin.</p> </li> <li> <p>Phenindione.</p> </li> </ol> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Heparins and derivative substances</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ol id="CD010155-list-0003"> <li> <p>Unfractionated heparin.</p> </li> <li> <p>Fractionated heparin or LMWHs such as dalteparin, enoxaparin, tinzaparin, nadroparin, bemiparin, certoparin, parnaparin and reviparin. </p> </li> </ol> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Factor Xa inhibitors</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ol id="CD010155-list-0004"> <li> <p>Synthetic pentasaccharide inhibitors of factor Xa such as fondaparinux and idraparinux.</p> </li> <li> <p>Direct factor Xa inhibitors such as rivaroxaban and apixaban.</p> </li> </ol> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Direct thrombin inhibitors</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lepirudin, hirudin, bivalirudin, desirudin, argatroban, dabigatran</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>LMWH: low‐molecular‐weight heparin</p> </div> </div> </section> <section id="CD010155-sec-0015"> <h3 class="title" id="CD010155-sec-0015">How the intervention might work</h3> <p>The pathophysiology of SCD has many facets, and no single treatment addresses all consequences of the disease. Hence, for treatment of patients with SCD, a combination of several interventions, depending on the expression of disease‐specific features and complications, is necessary. In addition to standardised pain management (<a href="./references#CD010155-bbs2-0016" title="deMontalembertM . Management of sickle cell disease. BMJ2008;337:a1397. [PMID: PMID: 18779222]">de Montalembert 2008</a>; <a href="./references#CD010155-bbs2-0033" title="MousaSA , Al MomenA , Al SayeghF , Al JaouniS , NasrullahZ , Al SaeedH , et al. Management of painful vaso-occlusive crisis of sickle-cell anemia: consensus opinion. Clinical and Applied Thrombosis/Haemostasis2010;16(4):365-76. [PMID: PMID: 20530056]">Mousa 2010</a><a href="./references#CD010155-bbs2-0034" title="ReesDC , WilliamsTN , GladwinMT . Sickle-cell disease. Lancet2010;376(9757):2018-31. [PMID: PMID: 21131035]">Rees 2010</a>; <a href="./references#CD010155-bbs2-0039" title="SteinbergMH . In the Clinic. Sickle cell disease. Annals of Internal Medicine2011;155(5):ITC31-15. [PMID: 21893620]">Steinberg 2011</a>), alternative approaches to therapy that have anti‐adhesion, anti‐inflammatory and anticoagulant effects have been proposed (<a href="./references#CD010155-bbs2-0033" title="MousaSA , Al MomenA , Al SayeghF , Al JaouniS , NasrullahZ , Al SaeedH , et al. Management of painful vaso-occlusive crisis of sickle-cell anemia: consensus opinion. Clinical and Applied Thrombosis/Haemostasis2010;16(4):365-76. [PMID: PMID: 20530056]">Mousa 2010</a>). </p> <p>The LMWHs exert their major anticoagulant effect by binding to antithrombin via a pentasaccharide, consequently inactivating Factor Xa and Factor IIa (<a href="./references#CD010155-bbs2-0025" title="HirshJ , LevineMN . Low molecular weight heparin. Blood1992;79(1):1-17. [PMID: PMID: 1309422]">Hirsh 1992</a>; <a href="./references#CD010155-bbs2-0026" title="HirshJ , WarkentinTE , ShaughnessySG , AnandSS , HalperinJL , RaschkeR , et al. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest2001;119 Suppl 1:64S-94S. [PMID: PMID: 11157643]">Hirsh 2001</a>; <a href="./references#CD010155-bbs2-0032" title="MousaSA , BozarthJ , BarrettJS . Pharmacodynamic properties of the low molecular weight heparin, tinzaparin: effect of molecular weight distribution on plasma tissue factor pathway inhibitor in healthy human subjects. Journal of Clinical Pharmacology2003;43(7):727-34. [PMID: PMID: 12856386]">Mousa 2003</a>). Furthermore, LMWHs have anti‐inflammatory properties in addition to their anticoagulant properties (<a href="./references#CD010155-bbs2-0012" title="CarrJA , ChoJS . Low molecular weight heparin suppresses tumor necrosis factor expression from deep vein thrombosis. Annals of Vascular Surgery2007;21(1):50-5. [PMID: PMID: 17349336]">Carr 2007</a>), in part caused by suppression of tumour necrosis factor‐α, which is released during blood clotting, and in part because of binding to P‐selectin to inhibit leukocyte migration. Vaso‐occlusion also leads to an altered nitric oxide (vasodilator) metabolism and contributes to vascular dysfunction (<a href="./references#CD010155-bbs2-0033" title="MousaSA , Al MomenA , Al SayeghF , Al JaouniS , NasrullahZ , Al SaeedH , et al. Management of painful vaso-occlusive crisis of sickle-cell anemia: consensus opinion. Clinical and Applied Thrombosis/Haemostasis2010;16(4):365-76. [PMID: PMID: 20530056]">Mousa 2010</a>), whereas LMWHs increase nitric oxide production and enhance vasodilating effects. </p> </section> <section id="CD010155-sec-0016"> <h3 class="title" id="CD010155-sec-0016">Why it is important to do this review</h3> <p>Management of vaso‐occlusive crises is complicated and may require multiple strategies and interventions. However, we are unaware of the existence of a current systematic review undertaken to examine available evidence for the benefits and harms of LMWHs. This is an update of a previously published version of this review (<a href="./references#CD010155-bbs2-0041" title="vanZuurenEJ , FedorowiczZ . Low-molecular-weight heparins for managing vaso-occlusive crises in people with sickle cell disease. Cochrane Database of Systematic Reviews2013, Issue 6. Art. No: CD010155. [DOI: 10.1002/14651858.CD010155.pub2]">van Zuuren 2013</a>). </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD010155-sec-0017" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD010155-sec-0017"></div> <p>To assess the effects of LMWHs in managing vaso‐occlusive crises in patients with SCD<i>.</i> </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD010155-sec-0018" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD010155-sec-0018"></div> <section id="CD010155-sec-0019"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD010155-sec-0020"> <h4 class="title">Types of studies</h4> <p>Randomised controlled clinical trials (RCTs) and controlled clinical trials (CCTs).</p> </section> <section id="CD010155-sec-0021"> <h4 class="title">Types of participants</h4> <p>People with SCD SS, HbSC, Sβ<sup>0</sup>, and Sβ<sup>+</sup> (confirmed by electrophoresis and sickle solubility test, with family studies or DNA tests as appropriate) of all ages and both sexes, in any setting. </p> </section> <section id="CD010155-sec-0022"> <h4 class="title">Types of interventions</h4> <p>Any LMWH administered subcutaneously compared with placebo or standard care for a period of up to two years. </p> <p>A <i>post hoc</i> change has been made to the protocol to include all LMWHs rather than just one (tinzaparin), as was previously included. This change is intended to provide a more comprehensive review of this treatment area. </p> </section> <section id="CD010155-sec-0023"> <h4 class="title">Types of outcome measures</h4> <section id="CD010155-sec-0024"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD010155-list-0005"> <li> <p>Pain</p> <ol id="CD010155-list-0006"> <li> <p>Intensity (expressed as scores obtained through any validated patient‐reported outcomes instrument, either generic or SCD specific) </p> </li> <li> <p>Duration</p> </li> </ol> </li> <li> <p>The requirement for opiate treatment</p> <ol id="CD010155-list-0007"> <li> <p>Dose</p> </li> <li> <p>Type</p> </li> <li> <p>Frequency</p> </li> </ol> </li> </ol> </p> </section> <section id="CD010155-sec-0025"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD010155-list-0008"> <li> <p>Number of serious complications of SCD (e.g. stroke, acute chest syndrome, infection, acute splenic sequestration). </p> </li> <li> <p>Number of other sickle‐related events (e.g. priapism, leg ulceration).</p> </li> <li> <p>Quality of life (e.g. absence from school, lost time at work, mobility) as assessed by any validated questionnaire, either generic or SCD specific. </p> </li> <li> <p>Hospitalisation (number and duration).</p> </li> <li> <p>Participant satisfaction with the medication as assessed by any appropriate and validated questionnaire (either generic or SCD specific). </p> </li> <li> <p>Adverse events associated with the use of anticoagulants (e.g. bleeding).</p> </li> </ol> </p> </section> </section> </section> <section id="CD010155-sec-0026"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD010155-sec-0027"> <h4 class="title">Electronic searches</h4> <p>Authors identified relevant studies from the Cystic Fibrosis and Genetic Disorders Group's Haemoglobinopathies Trials Register using the terms: (sickle cell OR (haemoglobinopathies AND general)) AND (bemiparin* OR certoparin* OR nadroparin* OR parnaparin* OR reviparin* OR ardeparin* OR danaparoid OR tinzaparin* OR dalteparin* OR enoxaparin* OR fondaparinux. </p> <p>The Haemoglobinopathies Trials Register is compiled from electronic searches of the Cochrane Central Register of Controlled Trials (CENTRAL) (updated each new issue of <i>The Cochrane Library</i>) and from weekly searches of MEDLINE. Unpublished work is identified by searching the abstract books of five major conferences: the European Haematology Association conference; the American Society of Hematology conference; the British Society for Haematology Annual Scientific Meeting; the Caribbean Health Research Council Meetings; and the National Sickle Cell Disease Program Annual Meeting. For full details of all searching activities for the register, please see the relevant section of the <a href="http://onlinelibrary.wiley.com/o/cochrane/clabout/articles/CF/frame.html" target="_blank">Cochrane Cystic Fibrosis and Genetic Disorders Group Module</a>. </p> <p>Date of the last search of the Cystic Fibrosis and Genetic Disorders Group's Haemoglobinopathies Trials Register: 28 September 2015. </p> </section> <section id="CD010155-sec-0028"> <h4 class="title">Searching other resources</h4> <p>The following additional resources were used:</p> <p> <ol id="CD010155-list-0009"> <li> <p>the bibliographical references of identified studies for citations to additional studies (EvZ, 30 November 2015); </p> </li> <li> <p>personal contact with corresponding authors of relevant trials or review authors and other experts (EvZ); </p> </li> <li> <p>clinical trials registries: <a href="http://clinicaltrials.gov/" target="_blank">ClinicalTrials.gov</a>; <a href="http://www.controlled-trials.com/" target="_blank">Current Controlled Trials</a> (across multiple registers) using the search terms (low‐molecular‐weight heparin OR sickle cell OR crises) AND trial (EvZ, 30 November 2015); </p> </li> <li> <p>conference proceedings of the International Society of Thrombosis and Hemostasis (ISTH) and of the Scientific Subcommittee of the ISTH (EvZ, 30 November 2015). </p> </li> </ol> </p> </section> </section> <section id="CD010155-sec-0029"> <h3 class="title" id="CD010155-sec-0029">Data collection and analysis</h3> <p>This is the first update of the original publication (<a href="./references#CD010155-bbs2-0041" title="vanZuurenEJ , FedorowiczZ . Low-molecular-weight heparins for managing vaso-occlusive crises in people with sickle cell disease. Cochrane Database of Systematic Reviews2013, Issue 6. Art. No: CD010155. [DOI: 10.1002/14651858.CD010155.pub2]">van Zuuren 2013</a>). </p> <section id="CD010155-sec-0030"> <h4 class="title">Selection of studies</h4> <p>Two review authors (EvZ and ZF) independently assessed the abstracts of trials resulting from the searches. They obtained full‐text copies of all relevant and potentially relevant trials, those appearing to meet the inclusion criteria and those for which details in the title and in the abstract were insufficient to allow a clear decision. The two review authors then independently assessed the full‐text articles. Any disagreements on the eligibility of trials were resolved through discussion and consensus. All irrelevant records were excluded, and details of the trials and the reasons for their exclusion were noted in the Characteristics of excluded studies in RevMan 5.1 (<a href="./references#CD010155-bbs2-0035" title="The Nordic Cochrane Centre, The Cochrane CollaborationReview Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.">Review Manager (Revman) 2014</a>). </p> </section> <section id="CD010155-sec-0031"> <h4 class="title">Data extraction and management</h4> <p>Two review authors (EvZ, ZF) entered details for the included trials into the tables in the '<a href="./references#CD010155-sec-0104" title="">Characteristics of included studies</a>' in RevMan 5.1 (<a href="./references#CD010155-bbs2-0035" title="The Nordic Cochrane Centre, The Cochrane CollaborationReview Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.">Review Manager (Revman) 2014</a>) and collected outcome data using a pre‐determined form designed for this purpose. Two review authors (EvZ, ZF) extracted data independently and in duplicate and included them if consensus was reached. Trial investigators were contacted and were asked to provide missing data or to clarify study details (see <a href="#CD010155-tbl-0005">Table 3</a>). </p> <div class="table" id="CD010155-tbl-0005"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Contact with investigators</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study ID</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Response</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Additional</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Comment</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010155-bbs2-0001" title="QariMH , AljaouniSK , AlardawiMS , FataniH , AlsayesFM , ZografosP , et al. Reduction of painful vaso-occlusive crisis of sickle cell anaemia by tinzaparin in a double-blind randomized trial. Thrombosis and Haemostasis2007;98(2):392-6. [PMID: PMID: 17721622]QariMH , MousaS , AlsaighMA , ZografosP , AljaouniSK , FataniH , et al. Tinzaparin in the management of painful vaso-occlusive crisis of sickle cell anaemia. Blood2005;106(11):Abstract no: 2340. ">Qari 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>E‐mail sent 6‐1‐2013</p> <p><a class="__cf_email__" data-cfemail="b5d8dac0c6d4c6f5d4d6c59bd0d1c0" href="/cdn-cgi/l/email-protection">[email protected]</a>, <a class="__cf_email__" data-cfemail="bbc8d3dad0dec995d6d4c8cedafbdad8cbd3c895dedfce" href="/cdn-cgi/l/email-protection">[email protected]</a></p> <p>Follow‐up e‐mail sent 15‐1‐2013<br/><a class="__cf_email__" data-cfemail="64090b11170517240507144a010011" href="/cdn-cgi/l/email-protection">[email protected]</a>; <a class="__cf_email__" data-cfemail="4b38232a202e39652624383e2a0b2a283b2338652e2f3e" href="/cdn-cgi/l/email-protection">[email protected]</a>; <a class="__cf_email__" data-cfemail="f99d8b88988b90b991968d94989095d79a9694" href="/cdn-cgi/l/email-protection">[email protected]</a> </p> <p>Both Mousa mail‐addressed seem to be incorrect. Could not find more recent ones.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010155-bbs2-0002" title="NCT01419977. Treatment of sickle cell patients hospitalized in pain crisis with prophylactic dose low-molecular-weight heparin (LMWH) versus placebo. www.clinicaltrials.gov/show/NCT01419977 (accessed 01 March 2013). ShahN , WillenS , TelenMJ , OrtelTL . Prophylactic dose low molecular weight heparin (dalteparin) for treatment of vaso-occlusive pain crisis in patients with sickle cell disease [abstract]. Blood2013;122(21):2241. [CENTRAL: 983639] ">Shah 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>E‐mail sent 30‐11‐2015<br/><a class="__cf_email__" data-cfemail="2846415a45415b40065b404940684c5d434d064d4c5d" href="/cdn-cgi/l/email-protection">[email protected]</a> </p> <p>Dear Dr Shah</p> <p>My colleagues and I are updating our Cochrane review (Low‐molecular‐weight heparins for managing vaso‐occlusive crises in people with sickle cell disease) and one of your studies have been identified as potentially eligible for inclusion (Prophylactic Dose Low Molecular Weight Heparin (dalteparin) For Treatment Of Vaso‐Occlusive Pain Crisis In Patients With Sickle Cell Disease. Blood 2013:122 (21) </p> <p>To enable us to further assess this trial for inclusion I would be obliged if you could you kindly provide us with the following missing trial details: </p> <p>1. the method used to generate the allocation sequence</p> <p>2. the method used to conceal the allocation sequence to ensure that <b>intervention allocations could not have been foreseen in advance of, or during, enrolment</b> i.e. participants and investigators enrolling participants could not foresee the upcoming assignment (this is not the same as blinding!!). </p> <p>3. How were patients and investigators blinded?</p> <p>4. In Clinicaltrials.gov it was stated that 34 participants were enrolled, but data are on 29. How many participants were initially randomised to each arm? We found the reasons for not including the five people, but unclear from which group </p> </td> </tr> </tbody> </table> </div> <p>The review authors extracted the following details.</p> <p> <ol id="CD010155-list-0010"> <li> <p>Trial methods</p> <ol id="CD010155-list-0011"> <li> <p>sequence generation</p> </li> <li> <p>method of concealment of allocation</p> </li> <li> <p>masking of participants, trialists and outcome assessors</p> </li> <li> <p>exclusion of participants after randomisation and proportion and reasons for losses at follow up </p> </li> </ol> </li> <li> <p>Participants</p> <ol id="CD010155-list-0012"> <li> <p>country of origin and study setting</p> </li> <li> <p>sample size</p> </li> <li> <p>age</p> </li> <li> <p>gender</p> </li> <li> <p>inclusion and exclusion criteria</p> </li> </ol> </li> <li> <p>Intervention group</p> <ol id="CD010155-list-0013"> <li> <p>type of LMWH</p> </li> <li> <p>dose and frequency</p> </li> <li> <p>duration of intervention and follow up</p> </li> </ol> </li> <li> <p>Control group</p> <ol id="CD010155-list-0014"> <li> <p>dose and frequency</p> </li> <li> <p>duration of intervention and follow up</p> </li> </ol> </li> <li> <p>Outcomes: primary and secondary outcomes mentioned in the '<a href="#CD010155-sec-0023">Types of outcome measures</a>' section of this review and categorised and grouped accordingly: short‐term data at three, six and 12 months and medium‐ to long‐term data (beyond one year). </p> </li> </ol> </p> <p>If stated in the trial reports, the review authors recorded the sources of funding of all included studies and used this information to help in assessment of the clinical heterogeneity and external validity of all included trials. </p> </section> <section id="CD010155-sec-0032"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (EvZ, ZF) independently assessed the selected trials using a simple contingency form and in accordance with the domain‐based evaluation described in Chapter 8 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> 5.1 (<a href="./references#CD010155-bbs2-0020" title="HigginsJPT , AltmanDG . Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook of Systematic Reviews of Interventions. Version 5.1 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.">Higgins 2011a</a>). The review authors compared evaluations and discussed and resolved any inconsistencies in these evaluations. </p> <p>The review authors assessed the following domains as having low, unclear or high risk of bias: </p> <p> <ol id="CD010155-list-0015"> <li> <p>sequence generation;</p> </li> <li> <p>allocation concealment;</p> </li> <li> <p>blinding (of participants, personnel and outcome assessors);</p> </li> <li> <p>incomplete outcome data addressed;</p> </li> <li> <p>free of selective outcome reporting;</p> </li> <li> <p>free of other bias.</p> </li> </ol> </p> <p>The review authors reported these assessments for each trial in the '<a href="./references#CD010155-sec-0104" title="">Characteristics of included studies</a>' tables and in the '<a href="#CD010155-sec-0032">Assessment of risk of bias in included studies</a>' section of this review. </p> <p>The authors categorised and reported the overall risk of bias of each of the included studies according to the following: </p> <p> <ul id="CD010155-list-0016"> <li> <p>low risk of bias (plausible bias unlikely to seriously alter the results) if all criteria met; </p> </li> <li> <p>unclear risk of bias (plausible bias that raises some doubt about the results) if one or more criteria assessed as unclear; or  </p> </li> <li> <p>high risk of bias (plausible bias that seriously weakens confidence in the results) if one or more criteria not met. </p> </li> </ul> </p> </section> <section id="CD010155-sec-0033"> <h4 class="title">Measures of treatment effect</h4> <p>The review authors sought advice from the Cochrane Cystic Fibrosis and Genetic Diseases Group with regard to statistical analysis for data synthesis. They analysed the data using RevMan 5.1 and report the results according to Cochrane Collaboration criteria (<a href="./references#CD010155-bbs2-0035" title="The Nordic Cochrane Centre, The Cochrane CollaborationReview Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.">Review Manager (Revman) 2014</a>). The authors analysed binary data and report risk ratios (RRs) with corresponding 95% confidence intervals (CIs); they also analysed continuous outcomes and report mean differences (MDs) between treatment groups and their 95% CIs. For future updates, if different scales or different units are collected for continuous outcomes, the review authors will calculate and present the data using the standardised mean difference (SMD). In addition, for repeated observations for individual participants and for events that may recur, the authors will follow chapter 9 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD010155-bbs2-0022" title="DeeksJJ , HigginsJPT , AltmanDG . Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook of Systematic Reviews of Interventions. Version 5.1 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org .">Higgins 2011c</a>). </p> </section> <section id="CD010155-sec-0034"> <h4 class="title">Unit of analysis issues</h4> <p>In future updates, if cluster‐randomised or cross‐over trials are included, they will be checked for unit of analysis errors based on the advice provided in chapters 16.3.4 and 16.4.4 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD010155-bbs2-0023" title="HigginsJPT , DeeksJJ , Altman DG on behalf of the CSMG . Chapter 16: Special topics in statistics. In: Higgins JPT, Green S (editors). Cochrane Handbook of Systematic Reviews of Interventions. Version 5.1 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.">Higgins 2011d</a>). For repeated observations per participant and for events that may recur, the review authors will follow guidance provided in chapters 9.3.4 and 9.3.5, respectively, of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD010155-bbs2-0023" title="HigginsJPT , DeeksJJ , Altman DG on behalf of the CSMG . Chapter 16: Special topics in statistics. In: Higgins JPT, Green S (editors). Cochrane Handbook of Systematic Reviews of Interventions. Version 5.1 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.">Higgins 2011d</a>). </p> </section> <section id="CD010155-sec-0035"> <h4 class="title">Dealing with missing data</h4> <p>The review authors contacted principal investigators of included trials to request missing data and followed the advice provided in chapter 16.1 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD010155-bbs2-0023" title="HigginsJPT , DeeksJJ , Altman DG on behalf of the CSMG . Chapter 16: Special topics in statistics. In: Higgins JPT, Green S (editors). Cochrane Handbook of Systematic Reviews of Interventions. Version 5.1 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.">Higgins 2011d</a>) (see <a href="#CD010155-tbl-0005">Table 3</a>). </p> </section> <section id="CD010155-sec-0036"> <h4 class="title">Assessment of heterogeneity</h4> <p>The review authors will assess in future updates (when more studies are included) clinical diversity between trials by examining trial characteristics, similarities between types of participants, the interventions and the outcomes as specified in the inclusion criteria.<br/>They will explore statistical heterogeneity using a Chi<sup>2</sup> test and the I<sup>2</sup> statistic, where I<sup>2</sup> values of 30% to 60% indicate moderate to high, 50% to 90% substantial, and 75% to 100% considerable heterogeneity. The review authors will consider heterogeneity to be significant when the P value is less than 0.10 for the Chi<sup>2</sup> test (<a href="./references#CD010155-bbs2-0019" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta-analyses. BMJ2003;327(7414):557-60.">Higgins 2003</a>). </p> </section> <section id="CD010155-sec-0037"> <h4 class="title">Assessment of reporting biases</h4> <p>In view of the low number of trials included, this assessment was not undertaken. In future updates, and if a sufficient number of trials (at least 10) assessing similar interventions are identified for inclusion in this review, the review authors plan to assess publication bias according to the recommendations on testing for funnel plot asymmetry as described in Chapter 10 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD010155-bbs2-0021" title="SterneJAC , EggerM , MoherD , on behalf of the Cochrane Bias Methods Group. Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S (editors). Cochrane Handbook of Systematic Reviews of Interventions. Version 5.1 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.">Higgins 2011b</a>). If asymmetry is identified, the review authors will attempt to assess other possible causes, and these will be explored in the discussion section of the review if appropriate. </p> </section> <section id="CD010155-sec-0038"> <h4 class="title">Data synthesis</h4> <p>Two review authors (ZF, EvZ) analysed the data in RevMan 5.1 (<a href="./references#CD010155-bbs2-0035" title="The Nordic Cochrane Centre, The Cochrane CollaborationReview Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.">Review Manager (Revman) 2014</a>) and reported them as specified in Chapter 9 of the <i>Cochrane Handbook for Systematic Reviews of Interventions </i>5.1 (<a href="./references#CD010155-bbs2-0022" title="DeeksJJ , HigginsJPT , AltmanDG . Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook of Systematic Reviews of Interventions. Version 5.1 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org .">Higgins 2011c</a>). They used a fixed‐effect model to analyse data from studies, unless in future updates they plan to identify moderate or higher heterogeneity (see classifications above), in which case they will use a random‐effects model to analyse data. </p> <p>We applied the GRADE approach for the two comparisons to rate the quality of the evidence of each of the prespecified outcomes (<a href="./references#CD010155-bbs2-0037" title="SchünemannH , BrożekJ , GuyattG , OxmanA , editors. GRADE handbook for grading quality of evidence and strength of recommendations. Updated October 2013. Available from www.guidelinedevelopment.org/handbook, The GRADE Working Group, 2013.">Schünemann 2013</a>). </p> </section> <section id="CD010155-sec-0039"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>In future updates, if a sufficient number of trials are included and if the authors identify moderate, substantial or considerable heterogeneity (<i>see</i> '<a href="#CD010155-sec-0036">Assessment of heterogeneity</a>'), they plan to carry out the following subgroup analyses based on: </p> <p> <ul id="CD010155-list-0017"> <li> <p>type of LMWH;</p> </li> <li> <p>type of SCD: sickle cell anaemia; haemoglobin SC disease; sickle cell β<sup>0‐</sup>thalassaemia; sickle cell β<sup>+‐</sup>thalassaemia; </p> </li> <li> <p>different dosing schedules.</p> </li> </ul> </p> </section> <section id="CD010155-sec-0040"> <h4 class="title">Sensitivity analysis</h4> <p>The review authors will undertake sensitivity analyses in future updates if a larger number of trials are included, to assess the robustness of their review results by repeating the analysis with the following adjustments: </p> <p> <ul id="CD010155-list-0018"> <li> <p>exclusion of trials with an unclear or high risk of bias for allocation concealment;</p> </li> <li> <p>exclusion of trials with an unclear or high risk of bias for blinding of outcome assessment;</p> </li> <li> <p>exclusion of trials with an unclear or high risk of bias for completeness of follow up; </p> </li> <li> <p>exclusion of CCTs.</p> </li> </ul> </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD010155-sec-0041" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD010155-sec-0041"></div> <section id="CD010155-sec-0042"> <h3 class="title">Description of studies</h3> <section id="CD010155-sec-0043"> <h4 class="title">Results of the search</h4> <p>Study selection was carried out independently by both review authors (EvZ and ZF), who retrieved three studies, one of which was a duplicate. No ongoing trial was identified. For further details, see the 'Study Flow Diagram' (<a href="#CD010155-fig-0001">Figure 1</a>). </p> <div class="figure" id="CD010155-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD010155-fig-0001" src="/cdsr/doi/10.1002/14651858.CD010155.pub3/media/CDSR/CD010155/image_n/nCD010155-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD010155-sec-0044"> <h4 class="title">Included studies</h4> <p>Two studies comprising 287 participants were included. One study included 253 participants (<a href="./references#CD010155-bbs2-0001" title="QariMH , AljaouniSK , AlardawiMS , FataniH , AlsayesFM , ZografosP , et al. Reduction of painful vaso-occlusive crisis of sickle cell anaemia by tinzaparin in a double-blind randomized trial. Thrombosis and Haemostasis2007;98(2):392-6. [PMID: PMID: 17721622]QariMH , MousaS , AlsaighMA , ZografosP , AljaouniSK , FataniH , et al. Tinzaparin in the management of painful vaso-occlusive crisis of sickle cell anaemia. Blood2005;106(11):Abstract no: 2340. ">Qari 2007</a>). The second study, currently available as an abstract only, included 34 participants (see the '<a href="./references#CD010155-sec-0104" title="">Characteristics of included studies</a>' tables of both studies). </p> <section id="CD010155-sec-0045"> <h5 class="title">Characteristics of the trial setting and methods</h5> <p>The Qari study was a randomised, double‐blind, placebo‐controlled trial conducted in three hospitals in Saudi Arabia (<a href="./references#CD010155-bbs2-0001" title="QariMH , AljaouniSK , AlardawiMS , FataniH , AlsayesFM , ZografosP , et al. Reduction of painful vaso-occlusive crisis of sickle cell anaemia by tinzaparin in a double-blind randomized trial. Thrombosis and Haemostasis2007;98(2):392-6. [PMID: PMID: 17721622]QariMH , MousaS , AlsaighMA , ZografosP , AljaouniSK , FataniH , et al. Tinzaparin in the management of painful vaso-occlusive crisis of sickle cell anaemia. Blood2005;106(11):Abstract no: 2340. ">Qari 2007</a>). The Shah study was a randomised, double‐blind, placebo‐controlled trial conducted in a university centre in the USA (<a href="./references#CD010155-bbs2-0002" title="NCT01419977. Treatment of sickle cell patients hospitalized in pain crisis with prophylactic dose low-molecular-weight heparin (LMWH) versus placebo. www.clinicaltrials.gov/show/NCT01419977 (accessed 01 March 2013). ShahN , WillenS , TelenMJ , OrtelTL . Prophylactic dose low molecular weight heparin (dalteparin) for treatment of vaso-occlusive pain crisis in patients with sickle cell disease [abstract]. Blood2013;122(21):2241. [CENTRAL: 983639] ">Shah 2013</a>). </p> </section> <section id="CD010155-sec-0046"> <h5 class="title">Characteristics of the participants</h5> <p>A total of 253 participants (men and women) of approximately 22 years of age with homozygous SCD and with painful vaso‐occlusive crises, severe enough to require narcotic analgesia, were included in the Qari trial (<a href="./references#CD010155-bbs2-0001" title="QariMH , AljaouniSK , AlardawiMS , FataniH , AlsayesFM , ZografosP , et al. Reduction of painful vaso-occlusive crisis of sickle cell anaemia by tinzaparin in a double-blind randomized trial. Thrombosis and Haemostasis2007;98(2):392-6. [PMID: PMID: 17721622]QariMH , MousaS , AlsaighMA , ZografosP , AljaouniSK , FataniH , et al. Tinzaparin in the management of painful vaso-occlusive crisis of sickle cell anaemia. Blood2005;106(11):Abstract no: 2340. ">Qari 2007</a>). In the Shah trial, 34 participants were randomised (both genders) with homozygous SCD, sickle cell‐haemoglobin C disease, or sickle cell/β<sup>0</sup>‐thalassaemia that were admitted with a diagnosis of vaso‐occlusive crisis (<a href="./references#CD010155-bbs2-0002" title="NCT01419977. Treatment of sickle cell patients hospitalized in pain crisis with prophylactic dose low-molecular-weight heparin (LMWH) versus placebo. www.clinicaltrials.gov/show/NCT01419977 (accessed 01 March 2013). ShahN , WillenS , TelenMJ , OrtelTL . Prophylactic dose low molecular weight heparin (dalteparin) for treatment of vaso-occlusive pain crisis in patients with sickle cell disease [abstract]. Blood2013;122(21):2241. [CENTRAL: 983639] ">Shah 2013</a>). </p> </section> <section id="CD010155-sec-0047"> <h5 class="title">Characteristics of the interventions</h5> <p>Tinzaparin at 175 IU/kg given subcutaneously versus placebo was evaluated over seven days in the Qari study (<a href="./references#CD010155-bbs2-0001" title="QariMH , AljaouniSK , AlardawiMS , FataniH , AlsayesFM , ZografosP , et al. Reduction of painful vaso-occlusive crisis of sickle cell anaemia by tinzaparin in a double-blind randomized trial. Thrombosis and Haemostasis2007;98(2):392-6. [PMID: PMID: 17721622]QariMH , MousaS , AlsaighMA , ZografosP , AljaouniSK , FataniH , et al. Tinzaparin in the management of painful vaso-occlusive crisis of sickle cell anaemia. Blood2005;106(11):Abstract no: 2340. ">Qari 2007</a>). All participants received standard analgesic therapy consisting of morphine at 1 mg/h given by intravenous infusion and rehydration with normal saline. In the Shah study, participants were given dalteparin 5000 units subcutaneously or placebo over seven days (<a href="./references#CD010155-bbs2-0002" title="NCT01419977. Treatment of sickle cell patients hospitalized in pain crisis with prophylactic dose low-molecular-weight heparin (LMWH) versus placebo. www.clinicaltrials.gov/show/NCT01419977 (accessed 01 March 2013). ShahN , WillenS , TelenMJ , OrtelTL . Prophylactic dose low molecular weight heparin (dalteparin) for treatment of vaso-occlusive pain crisis in patients with sickle cell disease [abstract]. Blood2013;122(21):2241. [CENTRAL: 983639] ">Shah 2013</a>). It was unclear if additional treatment was provided during these days. </p> </section> <section id="CD010155-sec-0048"> <h5 class="title">Characteristics of the outcome measures</h5> <p>In the Qari study six outcome measures were assessed, including pain intensity and duration, as well as complications and adverse events of the therapy (<a href="./references#CD010155-bbs2-0001" title="QariMH , AljaouniSK , AlardawiMS , FataniH , AlsayesFM , ZografosP , et al. Reduction of painful vaso-occlusive crisis of sickle cell anaemia by tinzaparin in a double-blind randomized trial. Thrombosis and Haemostasis2007;98(2):392-6. [PMID: PMID: 17721622]QariMH , MousaS , AlsaighMA , ZografosP , AljaouniSK , FataniH , et al. Tinzaparin in the management of painful vaso-occlusive crisis of sickle cell anaemia. Blood2005;106(11):Abstract no: 2340. ">Qari 2007</a>), whilst in <a href="./references#CD010155-bbs2-0002" title="NCT01419977. Treatment of sickle cell patients hospitalized in pain crisis with prophylactic dose low-molecular-weight heparin (LMWH) versus placebo. www.clinicaltrials.gov/show/NCT01419977 (accessed 01 March 2013). ShahN , WillenS , TelenMJ , OrtelTL . Prophylactic dose low molecular weight heparin (dalteparin) for treatment of vaso-occlusive pain crisis in patients with sickle cell disease [abstract]. Blood2013;122(21):2241. [CENTRAL: 983639] ">Shah 2013</a> only one of our predefined outcomes; i.e. reduction in pain, was addressed (see '<a href="./references#CD010155-sec-0104" title="">Characteristics of included studies</a>' for further details). </p> </section> </section> <section id="CD010155-sec-0049"> <h4 class="title">Excluded studies</h4> <p>No studies were excluded; just one study and a duplicate remained after assessment of the titles and abstracts resulting from the searches. </p> </section> </section> <section id="CD010155-sec-0050"> <h3 class="title">Risk of bias in included studies</h3> <p>The review authors assessed the included studies for risk of bias and reported the judgements for the individual domains in the risk of bias table associated with the study (<a href="./references#CD010155-sec-0104" title="">Characteristics of included studies</a>). The review authors have also presented these in the risk of bias graph in <a href="#CD010155-fig-0002">Figure 2</a> and in a summary of the risk of bias in <a href="#CD010155-fig-0003">Figure 3</a>. </p> <div class="figure" id="CD010155-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD010155-fig-0002" src="/cdsr/doi/10.1002/14651858.CD010155.pub3/media/CDSR/CD010155/image_n/nCD010155-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD010155-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD010155-fig-0003" src="/cdsr/doi/10.1002/14651858.CD010155.pub3/media/CDSR/CD010155/image_n/nCD010155-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD010155-sec-0051"> <h4 class="title">Allocation</h4> <section id="CD010155-sec-0052"> <h5 class="title">Sequence generation</h5> <p>The method used to generate the allocation sequence was not described in either study, therefore, both studies were assessed as having an unclear risk of bias for this domain. </p> </section> <section id="CD010155-sec-0053"> <h5 class="title">Allocation concealment</h5> <p>The method used to conceal the allocation sequence was not reported in either study, and a judgement of an unclear risk of bias was given for both studies for this domain. </p> </section> </section> <section id="CD010155-sec-0054"> <h4 class="title">Blinding</h4> <p>The reporting of the measures used to blind study participants and personnel from knowledge of which intervention a participant received was inadequate, as was information on blinding of the outcome assessment. Therefore, a clear judgement could not be made for these domains for both studies. </p> </section> <section id="CD010155-sec-0055"> <h4 class="title">Incomplete outcome data</h4> <p>No losses to follow up were reported in the Qari study, and this domain was therefore judged as having a low risk of bias (<a href="./references#CD010155-bbs2-0001" title="QariMH , AljaouniSK , AlardawiMS , FataniH , AlsayesFM , ZografosP , et al. Reduction of painful vaso-occlusive crisis of sickle cell anaemia by tinzaparin in a double-blind randomized trial. Thrombosis and Haemostasis2007;98(2):392-6. [PMID: PMID: 17721622]QariMH , MousaS , AlsaighMA , ZografosP , AljaouniSK , FataniH , et al. Tinzaparin in the management of painful vaso-occlusive crisis of sickle cell anaemia. Blood2005;106(11):Abstract no: 2340. ">Qari 2007</a>). However, five out of 34 participants (14.7%) were not included in the analyses in the Shah study and we judged this domain as at an unclear risk of bias for this (<a href="./references#CD010155-bbs2-0002" title="NCT01419977. Treatment of sickle cell patients hospitalized in pain crisis with prophylactic dose low-molecular-weight heparin (LMWH) versus placebo. www.clinicaltrials.gov/show/NCT01419977 (accessed 01 March 2013). ShahN , WillenS , TelenMJ , OrtelTL . Prophylactic dose low molecular weight heparin (dalteparin) for treatment of vaso-occlusive pain crisis in patients with sickle cell disease [abstract]. Blood2013;122(21):2241. [CENTRAL: 983639] ">Shah 2013</a>). </p> </section> <section id="CD010155-sec-0056"> <h4 class="title">Selective reporting</h4> <p>Athough the protocol was not available for the Qari study, all pre‐specified outcomes appear to have been reported, and this domain was assessed as having a low risk of bias (<a href="./references#CD010155-bbs2-0001" title="QariMH , AljaouniSK , AlardawiMS , FataniH , AlsayesFM , ZografosP , et al. Reduction of painful vaso-occlusive crisis of sickle cell anaemia by tinzaparin in a double-blind randomized trial. Thrombosis and Haemostasis2007;98(2):392-6. [PMID: PMID: 17721622]QariMH , MousaS , AlsaighMA , ZografosP , AljaouniSK , FataniH , et al. Tinzaparin in the management of painful vaso-occlusive crisis of sickle cell anaemia. Blood2005;106(11):Abstract no: 2340. ">Qari 2007</a>). The protocol for the Shah study was available and there appeared to be no evidence of selective reporting based on the data provided (<a href="./references#CD010155-bbs2-0002" title="NCT01419977. Treatment of sickle cell patients hospitalized in pain crisis with prophylactic dose low-molecular-weight heparin (LMWH) versus placebo. www.clinicaltrials.gov/show/NCT01419977 (accessed 01 March 2013). ShahN , WillenS , TelenMJ , OrtelTL . Prophylactic dose low molecular weight heparin (dalteparin) for treatment of vaso-occlusive pain crisis in patients with sickle cell disease [abstract]. Blood2013;122(21):2241. [CENTRAL: 983639] ">Shah 2013</a>). </p> </section> <section id="CD010155-sec-0057"> <h4 class="title">Other potential sources of bias</h4> <p>One of the investigators of the Qari study was employed by Leo Pharmaceutical Products (Athens, Greece), the manufacturer of tinzaparin, and a potential risk of bias cannot be excluded (<a href="./references#CD010155-bbs2-0001" title="QariMH , AljaouniSK , AlardawiMS , FataniH , AlsayesFM , ZografosP , et al. Reduction of painful vaso-occlusive crisis of sickle cell anaemia by tinzaparin in a double-blind randomized trial. Thrombosis and Haemostasis2007;98(2):392-6. [PMID: PMID: 17721622]QariMH , MousaS , AlsaighMA , ZografosP , AljaouniSK , FataniH , et al. Tinzaparin in the management of painful vaso-occlusive crisis of sickle cell anaemia. Blood2005;106(11):Abstract no: 2340. ">Qari 2007</a>). The same held true for the Shah study in that it was sponsored by Eisai Limited, the manufacturer of dalteparin (<a href="./references#CD010155-bbs2-0002" title="NCT01419977. Treatment of sickle cell patients hospitalized in pain crisis with prophylactic dose low-molecular-weight heparin (LMWH) versus placebo. www.clinicaltrials.gov/show/NCT01419977 (accessed 01 March 2013). ShahN , WillenS , TelenMJ , OrtelTL . Prophylactic dose low molecular weight heparin (dalteparin) for treatment of vaso-occlusive pain crisis in patients with sickle cell disease [abstract]. Blood2013;122(21):2241. [CENTRAL: 983639] ">Shah 2013</a>). </p> </section> </section> <section id="CD010155-sec-0058"> <h3 class="title" id="CD010155-sec-0058">Effects of interventions</h3> <p>See: <a href="./full#CD010155-tbl-0001"><b>Summary of findings 1</b> Tinzaparin compared to placebo for people with sickle cell disease</a>; <a href="./full#CD010155-tbl-0002"><b>Summary of findings 2</b> Dalteparin compared to placebo for people with sickle cell disease</a> </p> <section id="CD010155-sec-0059"> <h4 class="title">Tinzaparin versus placebo</h4> <p>One single study (253 participants) with an overall unclear to high risk of bias provided data for this comparison (<a href="./references#CD010155-bbs2-0001" title="QariMH , AljaouniSK , AlardawiMS , FataniH , AlsayesFM , ZografosP , et al. Reduction of painful vaso-occlusive crisis of sickle cell anaemia by tinzaparin in a double-blind randomized trial. Thrombosis and Haemostasis2007;98(2):392-6. [PMID: PMID: 17721622]QariMH , MousaS , AlsaighMA , ZografosP , AljaouniSK , FataniH , et al. Tinzaparin in the management of painful vaso-occlusive crisis of sickle cell anaemia. Blood2005;106(11):Abstract no: 2340. ">Qari 2007</a>). See also <a href="./full#CD010155-tbl-0001">summary of findings Table 1</a>. </p> <section id="CD010155-sec-0060"> <h5 class="title">Primary outcomes</h5> <section id="CD010155-sec-0061"> <h6 class="title">1. Pain</h6> <section id="CD010155-sec-0062"> <p><b>a. Intensity (expressed as scores obtained through any validated patient‐reported outcomes instrument, either generic or SCD specific<i>)</i> </b></p> <p>No precise data were reported; therefore, these were estimated from the graph‐plot in the report. The authors indicated that at days two and three, the pain severity score was lower in the tinzaparin group than in the placebo group (P &lt; 0.01 (ANOVA)), in addition to that at day 4 (P &lt; 0.05 (ANOVA)), and thus that tinzaparin resulted in more rapid resolution of pain as measured by the numerical pain scale (NMS). </p> </section> <section id="CD010155-sec-0063"> <p><b>b. Duration</b></p> <p>In the tinzaparin group, the duration of painful crises was 2.57 days (standard deviation (SD) 0.45) versus 4.35 days (0.78) for the placebo group; mean difference (MD) ‐1.78 days (95% CI ‐1.94 to ‐1.62; P &lt; 0.00001), and this difference was statistically significant in favour of tinzaparin (<a href="./references#CD010155-fig-0004" title="">Analysis 1.1</a>). </p> </section> </section> <section id="CD010155-sec-0064"> <h6 class="title">2. The requirement for opiate treatment</h6> <p>This outcome was inadequately reported, only that during the study all participants received standard analgesia therapy consisting of morphine at 1 mg/h given via intravenous infusion and rehydration with normal saline. </p> </section> </section> <section id="CD010155-sec-0065"> <h5 class="title">Secondary outcomes</h5> <section id="CD010155-sec-0066"> <h6 class="title">1. Number of serious complications of SCD</h6> <p>Not assessed.</p> </section> <section id="CD010155-sec-0067"> <h6 class="title">2. Number of other sickle‐related events</h6> <p>Not assessed.</p> </section> <section id="CD010155-sec-0068"> <h6 class="title">3. Quality of life (e.g. absence from school, lost time at work, mobility) as assessed by any validated questionnaire, either generic or SCD specific </h6> <p>Not assessed.</p> </section> <section id="CD010155-sec-0069"> <h6 class="title">4. Hospitalisation (number and duration)</h6> <p>Participants treated with tinzaparin had statistically significantly fewer hospitalisation days compared with those in the group treated with placebo. The number of days in the tinzaparin group was 7.08 (SD 1.8), and in the placebo group, the number was 12.06 (2.2), MD ‐4.98 days (95% CI ‐5.48 to ‐4.48; P &lt; 0.00001) (see <a href="./references#CD010155-fig-0005" title="">Analysis 1.2</a>). </p> </section> <section id="CD010155-sec-0070"> <h6 class="title">5. Participant satisfaction with the medication assessed by any appropriate and validated questionnaire (either generic or SCD specific) </h6> <p>Not assessed.</p> </section> <section id="CD010155-sec-0071"> <h6 class="title">6. Adverse events associated with the use of anticoagulants (e.g. bleeding)</h6> <p>Two minor bleeding events were reported in the tinzaparin group compared with none in the placebo group, RR 4.96 (95% CI 0.24 to 102.31; P = 0.30). The difference was not statistically significant (see <a href="./references#CD010155-fig-0006" title="">Analysis 1.3</a>). </p> </section> </section> </section> <section id="CD010155-sec-0072"> <h4 class="title">Dalteparin versus placebo</h4> <p>One study including 34 participants with an overall unclear risk of bias evaluated this comparison (<a href="./references#CD010155-bbs2-0002" title="NCT01419977. Treatment of sickle cell patients hospitalized in pain crisis with prophylactic dose low-molecular-weight heparin (LMWH) versus placebo. www.clinicaltrials.gov/show/NCT01419977 (accessed 01 March 2013). ShahN , WillenS , TelenMJ , OrtelTL . Prophylactic dose low molecular weight heparin (dalteparin) for treatment of vaso-occlusive pain crisis in patients with sickle cell disease [abstract]. Blood2013;122(21):2241. [CENTRAL: 983639] ">Shah 2013</a>). As data were summarized in a conference abstract, only limited data were available. See also <a href="./full#CD010155-tbl-0002">summary of findings Table 2</a>. </p> <section id="CD010155-sec-0073"> <h5 class="title">Primary outcomes</h5> <section id="CD010155-sec-0074"> <h6 class="title">1. Pain</h6> <section id="CD010155-sec-0075"> <p><b>a. Intensity (expressed as scores obtained through any validated patient‐reported outcomes instrument, either generic or SCD specific<i>)</i> </b></p> <p>After one day, based on a visual analogue scale (VAS) score rated 0 to 10, pain was reduced by 1.6 (0.4) in the 16 participants on dalteparin versus a reduction of 0.3 (0.5) in the 13 participants on placebo with a MD ‐1.30 (95% CI ‐1.60 to ‐1.00; P &lt; 0.00001), which favours dalteparin (<a href="./references#CD010155-fig-0007" title="">Analysis 2.1</a>). There was also a significant difference after three days in favour of dalteparin; the reductions were 2.4 (0.9) in nine participants on dalteparin and 0.9 (0.2) in 11 participants on placebo, MD ‐1.50 (95% CI ‐2.10 to ‐0.90) (P &lt; 0.00001) (<a href="./references#CD010155-fig-0007" title="">Analysis 2.1</a>). However, we have no information on the 14 out of 34 (41%) participants that are not included in the analysis, making these data less usable. </p> </section> <section id="CD010155-sec-0076"> <p><b>b. Duration</b></p> <p>Not assessed.</p> </section> </section> <section id="CD010155-sec-0077"> <h6 class="title">2. The requirement for opiate treatment</h6> <p>Not assessed.</p> </section> </section> <section id="CD010155-sec-0078"> <h5 class="title">Secondary outcomes</h5> <p>None of these outcomes were assessed.</p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD010155-sec-0079" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD010155-sec-0079"></div> <section id="CD010155-sec-0080"> <h3 class="title" id="CD010155-sec-0080">Summary of main results</h3> <p>Two studies comprising 287 participants were included. One study (253 participants), at an unclear to high risk of bias, reported that tinzaparin reduced hospitalisation days and pain, as well as pain intensity, more rapidly when compared with placebo. The quality of the evidence was rated mainly very low for several outcomes. Another study (34 participants), at an unclear risk of bias, showed that dalteparin reduced pain intensity more than placebo after one day (quality of evidence very low), and probably as well after three days. However, it is unclear if a difference of 1.30 on a visual analogue scale (VAS) is a clinically important difference. </p> <p>For further details, see <a href="./full#CD010155-tbl-0001">summary of findings Table 1</a> and <a href="./full#CD010155-tbl-0002">summary of findings Table 2</a>. </p> </section> <section id="CD010155-sec-0081"> <h3 class="title" id="CD010155-sec-0081">Overall completeness and applicability of evidence</h3> <p>There is incomplete evidence to support or refute the effectiveness of low‐molecular‐weight heparins (LMWHs) for the management of vaso‐occlusive crises in individuals with sickle cell disease (SCD). One of the two trials included in this review failed to address the majority of clinically relevant secondary outcomes, not least of all change in 'quality of life' and patient satisfaction; this somewhat limits the applicability of the evidence generated. However, the low number of adverse events reported appeared to illustrate the relative safety of the use of tinzaparin, albeit only over a short period of treatment time. The second study that was identified included a small (34) number of participants, provided even less information and reported mainly on pain intensity. There are still remaining gaps in the evidence for the effectiveness of LMWHs in managing vaso occlusive crises. </p> </section> <section id="CD010155-sec-0082"> <h3 class="title" id="CD010155-sec-0082">Quality of the evidence</h3> <section id="CD010155-sec-0083"> <h4 class="title">Limitations in study design and implementation</h4> <p>Although the study design of the included studies appeared to have been at best adequate, our assessment of the risk of bias for several domains in this study revealed some of the limitations in its implementation, which have been reported in the '<a href="#CD010155-sec-0050">Risk of bias in included studies</a>' section of this review. In particular, after unsuccessful attempts to contact the investigators in these studies, the methods used to generate the sequence and to conceal the allocation and the measures taken to blind investigators and participants remained unclear. Pain intensity and duration are key outcomes and require accurate assessment with the use of a valid and reliable tool. The numerical pain scale used in the Qari study did not appear to meet these criteria, making it difficult for the review authors to interpret the value of the reported outcomes and to further translate these into clinical practice (<a href="./references#CD010155-bbs2-0001" title="QariMH , AljaouniSK , AlardawiMS , FataniH , AlsayesFM , ZografosP , et al. Reduction of painful vaso-occlusive crisis of sickle cell anaemia by tinzaparin in a double-blind randomized trial. Thrombosis and Haemostasis2007;98(2):392-6. [PMID: PMID: 17721622]QariMH , MousaS , AlsaighMA , ZografosP , AljaouniSK , FataniH , et al. Tinzaparin in the management of painful vaso-occlusive crisis of sickle cell anaemia. Blood2005;106(11):Abstract no: 2340. ">Qari 2007</a>). Also, the minimal important difference of the VAS scale used in the Shah study for pain intensity has not yet been established (<a href="./references#CD010155-bbs2-0002" title="NCT01419977. Treatment of sickle cell patients hospitalized in pain crisis with prophylactic dose low-molecular-weight heparin (LMWH) versus placebo. www.clinicaltrials.gov/show/NCT01419977 (accessed 01 March 2013). ShahN , WillenS , TelenMJ , OrtelTL . Prophylactic dose low molecular weight heparin (dalteparin) for treatment of vaso-occlusive pain crisis in patients with sickle cell disease [abstract]. Blood2013;122(21):2241. [CENTRAL: 983639] ">Shah 2013</a>). </p> </section> <section id="CD010155-sec-0084"> <h4 class="title">Indirectness of the evidence</h4> <p>Participants in the included studies, in general, constituted a clinically representative sample, matching the inclusion criteria; therefore, the review authors had no significant concerns about the appropriateness of including participants identified in the review. </p> <p>Placebo‐controlled, rather than head‐to‐head trials, are still required to evaluate whether LMWHs have any beneficial effect on vaso‐occlusive crises. These trials should also consider evaluating other LMWHs. </p> <p>The Shah study only addressed one of our predefined outcomes; i.e. pain intensity, whereas the Qari study addressed several of our predefined outcomes (<a href="./references#CD010155-bbs2-0001" title="QariMH , AljaouniSK , AlardawiMS , FataniH , AlsayesFM , ZografosP , et al. Reduction of painful vaso-occlusive crisis of sickle cell anaemia by tinzaparin in a double-blind randomized trial. Thrombosis and Haemostasis2007;98(2):392-6. [PMID: PMID: 17721622]QariMH , MousaS , AlsaighMA , ZografosP , AljaouniSK , FataniH , et al. Tinzaparin in the management of painful vaso-occlusive crisis of sickle cell anaemia. Blood2005;106(11):Abstract no: 2340. ">Qari 2007</a>; <a href="./references#CD010155-bbs2-0002" title="NCT01419977. Treatment of sickle cell patients hospitalized in pain crisis with prophylactic dose low-molecular-weight heparin (LMWH) versus placebo. www.clinicaltrials.gov/show/NCT01419977 (accessed 01 March 2013). ShahN , WillenS , TelenMJ , OrtelTL . Prophylactic dose low molecular weight heparin (dalteparin) for treatment of vaso-occlusive pain crisis in patients with sickle cell disease [abstract]. Blood2013;122(21):2241. [CENTRAL: 983639] ">Shah 2013</a>). However, evidence was lacking on a requirement of opiates for pain relief and of participants' assessed outcomes (e.g. health‐related quality of life (HRQOL) and participants' level of satisfaction). Patient‐relevant outcomes are a pre‐requisite for informing evidence‐based clinical decision making, but the importance of patient‐reported outcomes (PROs), specifically those used in evaluating the impact of the intervention on quality of life, appears to have been underestimated by the investigators in the included study. </p> </section> <section id="CD010155-sec-0085"> <h4 class="title">Inconsistency of the results</h4> <p>As only two studies were included, assessment of inconsistency was not feasible. The results on reduction of pain intensity were in agreement for both studies. </p> </section> <section id="CD010155-sec-0086"> <h4 class="title">Imprecision of the results</h4> <p>Low occurrence of events and small sample size were the most important reasons for downgrading the quality of evidence for imprecision for most outcomes. </p> </section> <section id="CD010155-sec-0087"> <h4 class="title">Publication bias</h4> <p>Although our attempts to identify additional studies were unsuccessful, the possibility of unpublished research on this topic cannot be excluded. In future updates, and if further trials are identified for inclusion, we will assess publication bias as specified in the <a href="#CD010155-sec-0037">Assessment of reporting biases</a> section of this review. </p> </section> </section> <section id="CD010155-sec-0088"> <h3 class="title" id="CD010155-sec-0088">Potential biases in the review process</h3> <p>We made every attempt to limit bias in the review process by ensuring a comprehensive search for potentially eligible studies. The review authors' independent assessments of eligibility of studies for inclusion in this review minimised the potential for additional bias. </p> </section> <section id="CD010155-sec-0089"> <h3 class="title" id="CD010155-sec-0089">Agreements and disagreements with other studies or reviews</h3> <p>A number of literature reviews have described a range of management strategies for SCD‐related vaso‐occlusive crises; the most recent and relevant for our review is by Mousa, which referred to the Qari study identified in this systematic review and indicated that treatment with tinzaparin is "justified in the treatment of acute painful crisis in SCA based on that randomized controlled trial" (<a href="./references#CD010155-bbs2-0033" title="MousaSA , Al MomenA , Al SayeghF , Al JaouniS , NasrullahZ , Al SaeedH , et al. Management of painful vaso-occlusive crisis of sickle-cell anemia: consensus opinion. Clinical and Applied Thrombosis/Haemostasis2010;16(4):365-76. [PMID: PMID: 20530056]">Mousa 2010</a>; <a href="./references#CD010155-bbs2-0001" title="QariMH , AljaouniSK , AlardawiMS , FataniH , AlsayesFM , ZografosP , et al. Reduction of painful vaso-occlusive crisis of sickle cell anaemia by tinzaparin in a double-blind randomized trial. Thrombosis and Haemostasis2007;98(2):392-6. [PMID: PMID: 17721622]QariMH , MousaS , AlsaighMA , ZografosP , AljaouniSK , FataniH , et al. Tinzaparin in the management of painful vaso-occlusive crisis of sickle cell anaemia. Blood2005;106(11):Abstract no: 2340. ">Qari 2007</a>). The report specifies tinzaparin as adjuvant therapy in its "evidence based recommendations for pain management" but provides no indication of any systematic search of the literature, nor a critical appraisal of the cited references, but rather states that these recommendations are based on the "long term experience" of a panel of physicians and scientists. </p> <p>Several studies have suggested the possible use of tinzaparin to control the hypercoagulable state occurring in SCD (<a href="./references#CD010155-bbs2-0014" title="De FranceschiL . Pathophisiology of sickle cell disease and new drugs for the treatment. Mediterranean Journal of Hematology and Infectious Diseases2009;1(1):e2009024. [PMID: PMID:21415994]">De Franceschi 2009</a>; <a href="./references#CD010155-bbs2-0024" title="HiraniA , WeibelS , KaneGC . Acute chest syndrome and other pulmonary manifestations of sickle cell disease. Journal of Clinical Outcome Management2011;18(5):211-21.">Hirani 2011</a>; <a href="./references#CD010155-bbs2-0033" title="MousaSA , Al MomenA , Al SayeghF , Al JaouniS , NasrullahZ , Al SaeedH , et al. Management of painful vaso-occlusive crisis of sickle-cell anemia: consensus opinion. Clinical and Applied Thrombosis/Haemostasis2010;16(4):365-76. [PMID: PMID: 20530056]">Mousa 2010</a>), but all were based on one study (<a href="./references#CD010155-bbs2-0001" title="QariMH , AljaouniSK , AlardawiMS , FataniH , AlsayesFM , ZografosP , et al. Reduction of painful vaso-occlusive crisis of sickle cell anaemia by tinzaparin in a double-blind randomized trial. Thrombosis and Haemostasis2007;98(2):392-6. [PMID: PMID: 17721622]QariMH , MousaS , AlsaighMA , ZografosP , AljaouniSK , FataniH , et al. Tinzaparin in the management of painful vaso-occlusive crisis of sickle cell anaemia. Blood2005;106(11):Abstract no: 2340. ">Qari 2007</a>). Whilst these investigators recognize its potential use in managing vaso‐occlusive crises, they concur that it is still an experimental treatment option and provide no general recommendation as long as further studies have not been conducted. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD010155-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010155.pub3/media/CDSR/CD010155/urn:x-wiley:14651858:media:CD010155:CD010155-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD010155-fig-0001" src="/cdsr/doi/10.1002/14651858.CD010155.pub3/media/CDSR/CD010155/image_n/nCD010155-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010155.pub3/media/CDSR/CD010155/image_t/tCD010155-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010155.pub3/full#CD010155-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010155.pub3/media/CDSR/CD010155/image_n/nCD010155-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010155-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010155.pub3/media/CDSR/CD010155/urn:x-wiley:14651858:media:CD010155:CD010155-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD010155-fig-0002" src="/cdsr/doi/10.1002/14651858.CD010155.pub3/media/CDSR/CD010155/image_n/nCD010155-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010155.pub3/media/CDSR/CD010155/image_t/tCD010155-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010155.pub3/full#CD010155-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010155.pub3/media/CDSR/CD010155/image_n/nCD010155-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010155-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010155.pub3/media/CDSR/CD010155/urn:x-wiley:14651858:media:CD010155:CD010155-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD010155-fig-0003" src="/cdsr/doi/10.1002/14651858.CD010155.pub3/media/CDSR/CD010155/image_n/nCD010155-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010155.pub3/media/CDSR/CD010155/image_t/tCD010155-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010155.pub3/full#CD010155-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010155.pub3/media/CDSR/CD010155/image_n/nCD010155-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010155-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010155.pub3/media/CDSR/CD010155/urn:x-wiley:14651858:media:CD010155:CD010155-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Tinzaparin versus placebo, Outcome 1: Duration of the pain" data-id="CD010155-fig-0004" src="/cdsr/doi/10.1002/14651858.CD010155.pub3/media/CDSR/CD010155/image_n/nCD010155-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010155.pub3/media/CDSR/CD010155/image_t/tCD010155-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Tinzaparin versus placebo, Outcome 1: Duration of the pain</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010155.pub3/references#CD010155-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010155.pub3/media/CDSR/CD010155/image_n/nCD010155-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010155-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010155.pub3/media/CDSR/CD010155/urn:x-wiley:14651858:media:CD010155:CD010155-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Tinzaparin versus placebo, Outcome 2: Number of hospitalisations days" data-id="CD010155-fig-0005" src="/cdsr/doi/10.1002/14651858.CD010155.pub3/media/CDSR/CD010155/image_n/nCD010155-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010155.pub3/media/CDSR/CD010155/image_t/tCD010155-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Tinzaparin versus placebo, Outcome 2: Number of hospitalisations days</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010155.pub3/references#CD010155-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010155.pub3/media/CDSR/CD010155/image_n/nCD010155-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010155-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010155.pub3/media/CDSR/CD010155/urn:x-wiley:14651858:media:CD010155:CD010155-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Tinzaparin versus placebo, Outcome 3: Number of adverse events" data-id="CD010155-fig-0006" src="/cdsr/doi/10.1002/14651858.CD010155.pub3/media/CDSR/CD010155/image_n/nCD010155-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010155.pub3/media/CDSR/CD010155/image_t/tCD010155-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Tinzaparin versus placebo, Outcome 3: Number of adverse events</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010155.pub3/references#CD010155-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010155.pub3/media/CDSR/CD010155/image_n/nCD010155-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010155-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010155.pub3/media/CDSR/CD010155/urn:x-wiley:14651858:media:CD010155:CD010155-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Dalteparin versus placebo, Outcome 1: Reduction of pain" data-id="CD010155-fig-0007" src="/cdsr/doi/10.1002/14651858.CD010155.pub3/media/CDSR/CD010155/image_n/nCD010155-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010155.pub3/media/CDSR/CD010155/image_t/tCD010155-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: Dalteparin versus placebo, Outcome 1: Reduction of pain</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010155.pub3/references#CD010155-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010155.pub3/media/CDSR/CD010155/image_n/nCD010155-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table data-id="CD010155-tbl-0006"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Research recommendations based on a gap in the evidence of the effects of low‐molecular‐weight heparins for managing vaso‐occlusive crises in people with sickle cell disease</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Core elements</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Issues to consider</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Status of research for this review</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Evidence (E)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>What is the current state of the evidence?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>This systematic review identified one RCT, which provided insufficient high‐level evidence of the efficacy and safety of LMWH for managing vaso‐occlusive crises in people with SCD. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Population (P)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Diagnosis, disease stage, co‐morbidity, risk factors, gender, age, ethnic group, specific inclusion or exclusion criteria, clinical setting </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Inclusion criteria</b> </p> <p> <ul id="CD010155-list-0019"> <li> <p>Participants with sickle cell disease (all different genotypes).</p> </li> <li> <p>Painful vaso‐occlusive crisis severe enough to require narcotic analgesia.</p> </li> </ul> </p> <p><b>Exclusion criteria</b> </p> <p> <ul id="CD010155-list-0020"> <li> <p>Contraindication to LMWH.</p> </li> <li> <p>Pregnancy.</p> </li> <li> <p>Low platelet counts (&lt; 100,000/dl) or impaired haemostasis on admission in the form of INR &gt; 1.4 or prolonged APTT &gt; 5 seconds of the hospital normal range. </p> </li> <li> <p>History of CVA.</p> </li> <li> <p>Current aplasia.</p> </li> <li> <p>Acute chest syndrome.</p> </li> <li> <p>Exchange transfusion.</p> </li> <li> <p>Sequestration.</p> </li> <li> <p>Anticoagulant therapy for other etiology.</p> </li> <li> <p>Patients with painful crises within the month before this admission.</p> </li> <li> <p>Women on hormonal contraception.</p> </li> <li> <p>History of painful crisis within the preceding month.</p> </li> <li> <p>Other vascular complications of sickle cell disease (such as prior stroke, current aplasia, acute chest pain). </p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intervention (I)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Type, frequency, dose, duration, prognostic factor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The study duration should be 1 ‐ 2 weeks to assess a low‐molecular‐weight heparin. Concomitant pain medications allowed for ethical reasons but should be similarly available in both treatment arms. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Comparison (C)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Type, frequency, dose, duration, prognostic factor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No treatment or placebo treatment. Concomitant pain medications allowed for ethical reasons but should be similarly available in both treatment arms. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Outcome (O)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Which clinical or patient‐related outcomes will the researcher need to measure, improve, influence, or accomplish? Which methods of </p> <p>measurement should be used?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD010155-list-0021"> <li> <p>Pain: duration and intensity (assessed with a validated patient‐reported outcomes instrument either generic or SCD specific). </p> </li> </ul> <ul id="CD010155-list-0022"> <li> <p>Requirement for opiate treatment (dose, type and frequency).</p> </li> <li> <p>Number of serious complications of SCD (e.g. stroke, acute chest syndrome, infection, acute splenic sequestration). </p> </li> <li> <p>Number of other sickle‐related events (e.g. priapism, leg ulceration).</p> </li> <li> <p>Quality of life (e.g. absence from school, lost time at work, mobility) as assessed by any validated questionnaire, either generic or SCD specific. </p> </li> <li> <p>Hospitalisation (number and duration).</p> </li> <li> <p>Participant satisfaction with the medication assessed by any appropriate and validated questionnaire (either generic or SCD specific). </p> </li> <li> <p>Adverse events associated with the use of anticoagulants (e.g. bleeding).</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Time stamp (T)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Date of literature search or recommendation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 January 2013.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study type</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>What is the most appropriate study design to address the proposed question?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD010155-list-0023"> <li> <p>Randomised controlled trial (adequately powered / multi‐centred).</p> </li> <li> <p>Method: concealment of allocation sequence.</p> </li> <li> <p>Blinding: blinding of participants, trialists and outcome assessors.</p> </li> <li> <p>Setting: hospital / university.</p> </li> </ul> </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="3"> <div class="table-footnote"> <p>APTT: activated partial thromboplastin time<br/>CVA: cerebral vascular accident<br/>INR: international normalized ratio<br/>LMWH: low‐molecular‐weight heparins<br/>RCT: randomised controlled trial<br/>SCD: sickle cell disease </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Research recommendations based on a gap in the evidence of the effects of low‐molecular‐weight heparins for managing vaso‐occlusive crises in people with sickle cell disease</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010155.pub3/full#CD010155-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD010155-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Tinzaparin compared to placebo for people with sickle cell disease</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Tinzaparin compared to placebo for people with sickle cell disease</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population</b> : people with sickle cell disease<br/><b>Settings</b> : hospitals<br/><b>Intervention</b> : tinzaparin<br/><b>Comparison</b>: placebo </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No of Participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Placebo</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Tinzaparin</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pain intensity</b><br/>Numeric pain scale<br/>Follow up: mean 7 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment<sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>253<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low</b><sup>2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The authors reported at D2 and D3, the pain severity score was lower in the tinzaparin group than in the placebo group (P &lt; 0.01), to that at D4 (P &lt; 0.05) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pain duration</b><br/>Scale from: 1 to 7.<br/>Follow up: mean 7 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean pain duration in the control group was<br/><b>4.35 days</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean pain duration in the intervention group was<br/><b>1.78 lower</b><br/>(1.94 to 1.62 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>253<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low</b><sup>2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The duration of painful crises was almost 2 days shorter in the tinzaparin group</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>The requirement for opiate treatment</b><br/>Follow up: mean 7 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>253<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low</b><sup>2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This outcome was inadequately reported, only that during the study all participants received standard analgesia therapy consisting of morphine at 1 mg/h </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of serious complications of SCD</b> ‐ not measured </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not assessed</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of other sickle‐related events</b> ‐ not measured </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not assessed</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life (e.g. absence from school, lost time at work, mobility) as assessed by any validated questionnaire either generic or SCD specific)</b> ‐ not measured </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not assessed</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Hospitalisation (number and duration)</b><br/>Scale from: 0 to 12.<br/>Follow up: mean 7 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean hospitalisation (number and duration) in the control group was<br/><b>12.06 days</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean hospitalisation (number and duration) in the intervention group was<br/><b>4.98 lower</b><br/>(5.48 to 4.48 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>253<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low</b><sup>2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants treated with tinzaparin had almost 5 hospitalisation days less compared with those in the group treated with placebo </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participant satisfaction with the medication assessed by any appropriate and validated questionnaire (either generic or SCD specific)</b> ‐ not measured </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not assessed</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events associated with the use of anticoagulants (e.g. bleeding)</b><br/>Follow‐up: mean 7 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 4.96</b> <br/>(0.24 to 102.31) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>253<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>4,5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Two minor bleeding events were reported in the tinzaparin group compared with none in the placebo group </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI</b> : confidence interval; <b>RR</b>: risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality</b> : further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality</b> : further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality</b>: we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> No precise data were reported.<br/><sup>2</sup> Downgraded two levels for very serious risk of bias. Sequence generation is unclear as well as allocation concealment and measurements to blind the investigators and participants. A potential conflict of interest cannot be excluded as one of the investigators is an employee of the manufacturer of tinzaparin. The NMS scale is not a validated tool for pain assessment.<br/><sup>3</sup> Downgraded one level for serious imprecision. Total population size is less than 400<br/><sup>4</sup> We did not downgrade for risk of bias for this outcome<br/><sup>5</sup> Downgraded two levels for very serious imprecision due to very wide confidence intervals caused by low occurrence of events </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Tinzaparin compared to placebo for people with sickle cell disease</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010155.pub3/full#CD010155-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD010155-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Dalteparin compared to placebo for people with sickle cell disease</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Dalteparin compared to placebo for people with sickle cell disease</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with people with sickle cell disease<br/><b>Settings:</b> hospital<br/><b>Intervention:</b> dalteparin<br/><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No of Participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Placebo</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Dalteparin</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pain intensity</b><br/>VAS 0‐10. Scale from: 0 to 10.<br/>Follow‐up: mean 7 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean pain intensity in the control group was<br/><b>‐ 0.3</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean pain intensity in the intervention group was<br/><b>1.30 lower</b><br/>(1.60 to 1.00 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants in the dalteparin group had less pain than the participants in the placebo group after one day. After 3 days there was a 41% loss to follow‐up making data less usable </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pain duration</b> ‐ not measured </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not assessed</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>The requirement for opiate treatment</b> ‐ not measured </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not assessed</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of serious complications of SCD</b> ‐ not measured </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not assessed</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of other sickle‐related events</b> ‐ not measured </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not assessed</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life (e.g. absence from school, lost time at work, mobility) as assessed by any validated questionnaire either generic or SCD specific)</b> ‐ not measured </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not assessed</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Hospitalisation (number and duration)</b> ‐ not measured </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not assessed</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participant satisfaction with the medication assessed by any appropriate and validated questionnaire (either generic or SCD specific)</b> ‐ not measured </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not assessed</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events associated with the use of anticoagulants (e.g. bleeding)</b> ‐ not measured </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not assessed</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI</b>: confidence interval; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality</b> : further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality</b> : further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality</b> : further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality</b>: we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded one level for serious risk of bias as almost all domains were judged as unclear<br/><sup>2</sup> Downgraded two levels for serious imprecision. Very small sample size </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Dalteparin compared to placebo for people with sickle cell disease</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010155.pub3/full#CD010155-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD010155-tbl-0003"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Glossary of Terms</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Term</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Definition</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Anticoagulant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>A substance that prevents coagulation (clotting) of blood.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Genotype</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The genotype of an individual is the set of inherited instructions carried within its genetic code. Not all organisms with the same genotype look or act the same way because appearance and behaviour are modified by environmental and developmental conditions. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Haemoglobin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The iron‐containing oxygen‐transport metalloprotein in the red blood cells. Haemoglobin in the blood carries oxygen from the respiratory organs (lungs) to the rest of the body. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Heterozygous</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>A cell is said to be heterozygous when it contains two different alleles of a gene.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Homozygosity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>A cell is said to be homozygous for a particular gene when identical alleles of the gene are present on both homologous chromosomes. The individual is called a <i>homozygote</i>. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lyse</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>To destroy or dissolve cells.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Necrosis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The premature death of cells in living tissue.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Phenotype</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The composite of an individual's observable characteristics or traits, such as its morphology, development, biochemical or physiological properties and behaviour. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P‐selectin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>A cell adhesion molecule (CAM) on the surfaces of activated endothelial cells (thin layer of cells that lines the interior surface of blood vessels), which line the inner surface of blood vessels, and activated platelets (thin layer of cells that lines the interior surface of blood vessels). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Polarize</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Aggregate.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tumour necrosis factor‐α</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>A cytokine; cell‐signalling (transmitting information between cells) protein involved in systemic inflammation; a member of a group of cytokines that stimulate the acute phase reaction. </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Glossary of Terms</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010155.pub3/full#CD010155-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD010155-tbl-0004"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Classes of anticoagulants</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Coumarins (vitamin K antagonists)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ol id="CD010155-list-0002"> <li> <p>Warfarin.</p> </li> <li> <p>Acenocoumarol and phenprocoumon.</p> </li> <li> <p>Atromentin.</p> </li> <li> <p>Phenindione.</p> </li> </ol> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Heparins and derivative substances</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ol id="CD010155-list-0003"> <li> <p>Unfractionated heparin.</p> </li> <li> <p>Fractionated heparin or LMWHs such as dalteparin, enoxaparin, tinzaparin, nadroparin, bemiparin, certoparin, parnaparin and reviparin. </p> </li> </ol> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Factor Xa inhibitors</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ol id="CD010155-list-0004"> <li> <p>Synthetic pentasaccharide inhibitors of factor Xa such as fondaparinux and idraparinux.</p> </li> <li> <p>Direct factor Xa inhibitors such as rivaroxaban and apixaban.</p> </li> </ol> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Direct thrombin inhibitors</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lepirudin, hirudin, bivalirudin, desirudin, argatroban, dabigatran</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="2"> <div class="table-footnote"> <p>LMWH: low‐molecular‐weight heparin</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Classes of anticoagulants</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010155.pub3/full#CD010155-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD010155-tbl-0005"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Contact with investigators</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study ID</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Response</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Additional</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Comment</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010155-bbs2-0001" title="QariMH , AljaouniSK , AlardawiMS , FataniH , AlsayesFM , ZografosP , et al. Reduction of painful vaso-occlusive crisis of sickle cell anaemia by tinzaparin in a double-blind randomized trial. Thrombosis and Haemostasis2007;98(2):392-6. [PMID: PMID: 17721622]QariMH , MousaS , AlsaighMA , ZografosP , AljaouniSK , FataniH , et al. Tinzaparin in the management of painful vaso-occlusive crisis of sickle cell anaemia. Blood2005;106(11):Abstract no: 2340. ">Qari 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>E‐mail sent 6‐1‐2013</p> <p><a class="__cf_email__" data-cfemail="c2afadb7b1a3b182a3a1b2eca7a6b7" href="/cdn-cgi/l/email-protection">[email protected]</a>, <a class="__cf_email__" data-cfemail="25564d444e40570b484a565044654446554d560b404150" href="/cdn-cgi/l/email-protection">[email protected]</a></p> <p>Follow‐up e‐mail sent 15‐1‐2013<br/><a class="__cf_email__" data-cfemail="83eeecf6f0e2f0c3e2e0f3ade6e7f6" href="/cdn-cgi/l/email-protection">[email protected]</a>; <a class="__cf_email__" data-cfemail="cebda6afa5abbce0a3a1bdbbaf8eafadbea6bde0abaabb" href="/cdn-cgi/l/email-protection">[email protected]</a>; <a class="__cf_email__" data-cfemail="2a4e585b4b58436a42455e474b434604494547" href="/cdn-cgi/l/email-protection">[email protected]</a> </p> <p>Both Mousa mail‐addressed seem to be incorrect. Could not find more recent ones.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010155-bbs2-0002" title="NCT01419977. Treatment of sickle cell patients hospitalized in pain crisis with prophylactic dose low-molecular-weight heparin (LMWH) versus placebo. www.clinicaltrials.gov/show/NCT01419977 (accessed 01 March 2013). ShahN , WillenS , TelenMJ , OrtelTL . Prophylactic dose low molecular weight heparin (dalteparin) for treatment of vaso-occlusive pain crisis in patients with sickle cell disease [abstract]. Blood2013;122(21):2241. [CENTRAL: 983639] ">Shah 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>E‐mail sent 30‐11‐2015<br/><a class="__cf_email__" data-cfemail="f59b9c87989c869ddb869d949db591809e90db909180" href="/cdn-cgi/l/email-protection">[email protected]</a> </p> <p>Dear Dr Shah</p> <p>My colleagues and I are updating our Cochrane review (Low‐molecular‐weight heparins for managing vaso‐occlusive crises in people with sickle cell disease) and one of your studies have been identified as potentially eligible for inclusion (Prophylactic Dose Low Molecular Weight Heparin (dalteparin) For Treatment Of Vaso‐Occlusive Pain Crisis In Patients With Sickle Cell Disease. Blood 2013:122 (21) </p> <p>To enable us to further assess this trial for inclusion I would be obliged if you could you kindly provide us with the following missing trial details: </p> <p>1. the method used to generate the allocation sequence</p> <p>2. the method used to conceal the allocation sequence to ensure that <b>intervention allocations could not have been foreseen in advance of, or during, enrolment</b> i.e. participants and investigators enrolling participants could not foresee the upcoming assignment (this is not the same as blinding!!). </p> <p>3. How were patients and investigators blinded?</p> <p>4. In Clinicaltrials.gov it was stated that 34 participants were enrolled, but data are on 29. How many participants were initially randomised to each arm? We found the reasons for not including the five people, but unclear from which group </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Contact with investigators</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010155.pub3/full#CD010155-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010155-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Tinzaparin versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Duration of the pain <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Number of hospitalisations days <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Number of adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Tinzaparin versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010155.pub3/references#CD010155-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010155-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Dalteparin versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 Reduction of pain <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.1 Reduction of pain after 1 day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.2 Reduction of pain after 3 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Dalteparin versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010155.pub3/references#CD010155-tbl-0008">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD010155.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD010155-note-0009">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD010155-note-0007">فارسی</a> </li> <li class="section-language"> <a class="" href="ms#CD010155-note-0008">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD010155-note-0006">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010155\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010155\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010155\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010155\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010155\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010155\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010155\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010155\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010155\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010155\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010155\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010155\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010155\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010155\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010155\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010155\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010155\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010155\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=cdmLYOAV&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010155.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD010155.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD010155.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD010155.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010155.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740724366045"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD010155.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740724366049"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD010155.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918e610aeafaf3fd',t:'MTc0MDcyNDM2Ni4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 